

# ARCH REINSURANCE EUROPE UNDERWRITING DAC 2022 SOLVENCY AND FINANCIAL CONDITION REPORT

Arch Reinsurance Europe Underwriting dac 08 April 2023

# **SOLVENCY AND FINANCIAL CONDITION REPORT**

# **Table of Contents**

Summar	у	1
SECTION	I A – Business and Performance	5
A.1	Business	5
A.2	Underwriting Performance.	7
A.3	Investment Performance	10
A.4	Performance of other activities	11
A.5	Any other information	12
SECTION	IB – System of Governance	13
B.1	General information on the system of governance	13
B.2	Fit and proper requirements	19
B.3	Risk management system including the own risk and solvency assessment	20
B.4	Internal control system	26
B.5	Internal audit function	27
B.6	Actuarial function	29
B.7	Outsourcing	29
B.8	Assessment	30
B.9	Any other information	30
SECTION	I C – Risk Profile	31
C.1	Underwriting risk	31
C.2	Market risk	33
C.3	Credit risk	36
C.4	Liquidity risk	37
C.5	Operational risk	38
C.6	Other material risks	40
C.7	Any other information	40
SECTION	I D – Valuation for Solvency Purposes	41
D.1	Assets	41
D.2	Technical provisions	44
D.3	Other liabilities	51
D.4	Alternative methods for valuation	52

Appendix	1 – ACGL Organizational Structure	
E.6	Any other information	57
E.5	Non-compliance with the MCR and non-compliance with the SCR	57
E.4	Differences between the standard formula and any internal model used	57
E.3	Use of the duration-based equity risk sub-module in the calculation of the SCR	57
E.2	Solvency Capital Requirement and Minimum Capital Requirement	55
E.1	Own Funds	53
SECTION	E – Capital Management	53
D.5	Any other information.	52

Arch Reinsurance Europe Underwriting dac ("ARE" or "the Company") is an Irish regulated composite reinsurance entity authorised by the Central Bank of Ireland ("CBI"). The Company's ultimate parent is Arch Capital Group Ltd. ("ACGL" and, together with its subsidiaries, the "Group" or the "Arch Group"), whose common shares are listed and traded on the NASDAQ stock market in the U.S. The Company is a property and casualty reinsurance underwriting company writing a diversified portfolio, both in terms of product mix and geography, in non-commoditised niche areas primarily.

## **Business, Strategy & Performance**

Gross written premium ("GWP") for 2022 was €762.4m, which is 57% up compared to prior year. Net underwriting profit increased to €23m up from €6.5m in 2021. The increase in net underwriting profit was driven by the growth achieved in gross written and net earned premium and driven by the Company's existing book of business as well as new business. Due to the increase in net earned premium the expense ratio was lower and this despite an increase in operating expenses. Pre-tax the Company has a loss including investment income amounting to €47.4m which compared to €14.6m for the prior year. This pre-tax loss is attributed to unrealised losses primarily on the Company's fixed income bond portfolios whose market values were impacted negatively by increases in interest rates in US and UK.

The effects of the ongoing Covid-19 challenges around the world have largely subsided as from April 2022 in most parts of the world except for the Far East. The industry has fared well throughout this period both operationally and balancing supply and demand. Related claims (inter alia non-damage business interruption, event, and travel cancellation) are mainly from underwriting year 2020 and settled in many places without going to court. There were very few bankruptcies, whether corporate or individual, as economic recovery was very strong on the back of a high consumer confidence. In fact, Credit & Surety ("C&S") results through this pandemic period are trending at their best since 2010/2011 and continued to do so during 2022.

Natural Catastrophe ("Nat Cat") claims during 2022 in the US (Ian, \$50-60 billion, Sept), Europe (French hail EUR 6-8 billion, June/July), floods in South Africa (April) European winter storms (Feb), and Australian flood (Feb) have taken their toll on reinsurers' results. Besides a substantially increased loss load from Nat Cat events, the industry is facing a higher loss load from substantial increases in material and labor cost as well as cost of care. What has materially changed is the interest rate increases which dampen the industry's capital base due to unrealized losses on their investments. Pricing and conditions continue to tighten in Property (Nat Cat, Per Risk, Political Violence, War, Engineering, Facultative), Professional Liability, Cyber, Aviation and Excess Liability. Key markets impacted by this change are the US, U.K., Continental Europe, Japan, Australia, and South Africa.

The net impact to the Company from those industry events was very manageable and largely limited to losses in South Africa (property) and Brazil (agriculture) and balanced by positive prior year developments from multiple lines.

The Company has remained faithful to its underwriting philosophy of writing business that meets our return on equity ("ROE") criteria whilst taking advantage of opportunities that emerged either as a result of improved market conditions or the overall improvement in pricing in certain lines of business. The growth of the business compared to 2021 was largely a result of i) continued hardening market conditions in certain geographies, particularly property both treaty and facultative, ii) expansion of shares in

attractive markets to us and iii) the identification of those new opportunities, including but not limited to some niche opportunities in motor, credit & surety, agriculture and specialty casualty.

The Company purchases reinsurance on the business it writes to efficiently manage return on capital with partners that value our origination and underwriting capabilities. The Company's external reinsurance purchases are in the form of both excess of loss and quota share agreements. In addition, the Company cedes 85% of its net retained premium under a quota share agreement with a related group entity, Arch Reinsurance Ltd. ("ARL"), a Bermuda domiciled company with \$14.9 billion (2021: \$15.6 billion) of capital, comprised of shareholders' equity and debt as at 31 December 2022. More details about the Company's business and performance can be found in Section A.

## System of governance

The Company maintains an effective system of governance, which provides for sound and prudent management of its integrated operations.

The Company has designed its system of governance to achieve the following:

- Maintain an adequately transparent organizational structure that has well-defined, clear, consistent and documented lines of responsibility across the integrated operations;
- Ensure staff have the skills, knowledge and expertise necessary to properly discharge their assigned responsibilities;
- Establish and maintain processes to achieve effective internal reporting and communication of information at all relevant levels within the integrated operations;
- Maintain information systems that produce sufficient, reliable, consistent, timely and relevant information concerning all business activities, the commitments assumed and the risks to which the integrated operations are exposed;
- Safeguard the security, integrity and confidentiality of information, taking into account the nature of the information in question; and
- Ensure that outsourced responsibilities are delegated and managed appropriately, with ultimate responsibility residing with the Board.

The system of governance is based on the principle of proportionality, such that systems and controls are proportionate to the nature, scale and complexity of the integrated Company's operations.

In this regard, the Company's Board of Directors ("Board") monitors key aspects of the business and is assisted where appropriate by the Risk and Audit Committees of the Board.

It is not deemed appropriate or proportionate, given the scale of the business and the governance structure in place to appoint an Investment Committee, Nomination Committee or a Remuneration Committee. In addition, the Board reviews information that would otherwise be addressed by such committees at its meetings.

The principles and requirements of the system of governance, particularly risk management, internal control, internal audit and outsourcing, are the responsibility of the Board. While retaining these responsibilities, the Board has delegated the authority for day-to-day risk management to ARE's Executive team. The Company's Chief Risk Officer ("CRO") monitors the Risk Management Framework for operating effectiveness and reports to the Risk Committee and Board as appropriate.

The Board has approved formal policies, which are a component of the Company's Governance Structure.

The system of governance is assessed via reviews by the Head of Compliance ("HOC"), together with the CRO and periodic evaluation by Internal Audit. All related findings and/or reports are presented to the Audit Committee and the Board. Section B provides details on the Company's governance system.

#### **Risk Profile**

The Company's risk appetite framework provides an expression of the level of risk it is willing to accept in pursuit of its strategic objectives. The risk appetite framework provides quantitative and qualitative statements which are used to define the general attitude within the organization towards the desired level of risk. It not only supports the Company's risk management framework, it also enables the Company to make informed business decisions having regard to the key risks to which it may be exposed by such a decision.

In general, ARE has an appetite for insurance (underwriting) risk and a tolerance for other forms of risk. The risk philosophy of ARE encompasses all major risks and focuses on attaining the following business objectives:

- Underwrite business that meets agreed targeted returns;
- Underwrite business with selected cedants;
- Underwrite only carefully selected business lines;
- Manage underwriting volumes in line with the business cycle; and
- Limit the downside risk such that the Company maintains a sufficient solvency margin.

To meet these objectives and the Company's overall strategy, performance against risk appetites and risk tolerances & limits metrics, as articulated in the Company's Risk Appetite Statement, are monitored by the CRO and reported on to the Risk Committee on a quarterly basis with defined escalation process for breaches of these key metrics.

No reinsurance recoverability or impairment concerns have arisen during 2022 and the overall credit quality of outstanding balances consistently remained above the Company's risk tolerance.

The Company's liquidity also remained strong throughout 2022 with no adverse impact resulting in delays in premium collections or accelerated claims settlements. Overall liquidity remained in line with or above the Company's liquidity risk tolerance limit. In line with the Company's investment strategy and related duration matching it was not necessary to crystallize unrealized investment losses during the year.

The Company's risk profile is detailed in <u>Section C</u>.

#### **Valuation for Solvency II purposes**

The Company prepares its financial statements in accordance with Generally Accepted Accounting Practice ("GAAP") in Ireland comprised of accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102. This Financial Reporting Standard is applicable in the UK and Republic of Ireland and promulgated by the Institute of Chartered Accountants in Ireland.

The Company's Solvency II balance sheet is prepared on an economic or fair value basis. The most significant differences between the Solvency II balance sheet and the balance sheet on a GAAP basis arise from;

- the valuation of technical provisions and reinsurer's share of technical provisions;
- the valuation of holdings in related undertakings;

- the valuation of insurance and intermediary balances receivable and reinsurance balances payable;
- the valuation of deferred acquisition costs / deferred ceding commissions; and
- the valuation of deferred tax asset / deferred tax liability.

<u>Section D</u> provides reconciliation between the valuation of assets and liabilities under GAAP and under Solvency II along with further details on valuation for Solvency II purposes.

## **Capital Management**

The Company's SCR coverage ratio as at 31 December 2022 was 181.9% with Eligible Own Funds of €843.0m and a SCR of €463.5m. ARE derives its SCR from the Standard Formula approach. The Company's MCR coverage ratio as at 31 December 2022 was 725.0%. There were no material changes in the SCR calculation during the year. The Company has a strong capital base enabling it to meet its solvency requirements and to facilitate the level of activity anticipated throughout the planning period and within the Company's Own Risk and Solvency Assessment ("ORSA"). Section E provides details about the Company's Capital Management.

#### Covid-19 – risk impact review

The Company's ultimate reserves for losses associated with pandemic were stable during 2022 with no material new claims arising and some settlements of reserved claims taking place.

#### A.1 Business

## A.1.1 Name and Legal Form of the Undertaking

ARE is incorporated in Ireland as a designated activity company ("dac"). A dac is a corporate form for a private company limited by shares, which activities are limited by its objects clause, and its constitution comprises a memorandum and articles of association. The address of the registered office of the Company is:

Arch Reinsurance Europe Underwriting dac Level 2, Block 3, The Oval 160 Shelbourne Road, Ballsbridge Dublin 4, Ireland

This Solvency and Financial Condition Report ("SFCR") covers ARE on a solo basis.

#### A.1.2 Insurance Supervisor and Group Supervisor

Insurance Supervisor
Central Bank of Ireland ("CBI")
PO Box 559
Dublin 1, Ireland

Group Supervisor
Bermuda Monetary Authority ("BMA")
BMA House
43 Victoria Street
Hamilton HM 12 Bermuda

#### A.1.3 External Auditor

Grant Thorton 13 – 18 City Quay D02 ED70 Dublin, Ireland

#### A.1.4 Description of the ownership details including proportion of ownership interest

Arch Financial Holdings Europe II Limited, a private company limited by shares and incorporated in Ireland, owns 100% of the equity share capital of the Company.

### A.1.5 Group Structure

The Company's ultimate parent and ultimate controlling party is ACGL, a Bermuda public limited liability company. ACGL prepares group financial statements and is the largest group for which group financial statements are drawn up and of which the Company is a member. Copies of the ACGL group financial statements are available on ACGL's website located at <a href="https://www.archgroup.com">www.archgroup.com</a> or on the website of the U.S. Securities and Exchange Commission located at <a href="https://www.sec.gov">www.sec.gov</a>.

An organization chart illustrating ARE's position in the Group is included as Appendix 1.

## A.1.6 Material Lines of Business and Geographical areas where business is conducted

The following tables set forth summary information regarding Gross premiums written, by major business line and geographical region for the year to December 31 2022;

Gross Written Premium ('000 EUR) Major Line of business	2022	2021
Casualty	179,538	146,130
Other Property	168,824	100,675
Other Specialty	412,321	235,733
Marine & Other	1,737	1,197
Total	762,420	483,735
Gross Written Premium ('000 EUR) Geographic Region	2022	2021
Europe	477,262	308,780
Asia Pacific	139,021	92,540
Southern & Central America	23,804	15,951
Middle East & Africa	75,146	36,462
North America	23,046	13,797
Other	24,141	16,205
Total	762,420	483,735

## A.1.7 Significant Business or Other Events

No significant business or other events occurred during 2022 that had a material impact on the Company. Noteworthy was the impact of inflation in terms of its impact on loss costs, insured values, reinsurance rates in certain lines of business as well as the market value of the Company's bond portfolios resulting in significant unrealised losses. The Company believes it is well reserved for liabilities and is generally not required to realise bond investment losses to meet its liquidity requirements.

The Company is impacted by Brexit by virtue of its UK Branch presence. The UK Prudential Regulatory Authority ("PRA") has introduced a Temporary Permissions Regime ("TPR") which enables existing

Freedom of Establishment ("FOE") operations, such as the Company's branch, to apply to continue to operate on an FOE basis whilst making an application to establish a Third Country branch. The Company has availed of the TPR and made an application for the approval of a Third Country branch in 2022. This application is being reviewed by the PRA and awaits approval.

#### A.2 Underwriting Performance

Since the Company prepares its financial statements in accordance with Generally Accepted Accounting Practice in Ireland<sup>1</sup>, the underwriting performance information given in this section is on a GAAP (Ireland) basis. The following table summarizes the performance, by major line of business in Euro '000, for the technical account for year ended 31 December 2022.

	Casualty	Property	Other Specialty	Marine &	Total YTD
				Other	
	€'000	€'000	€'000	€'000	€'000
Gross premiums written	179,538	168,823	412,321	1,737	762,420
Net premiums written	19,427	19,977	40,557	153	80,114
Net premiums earned	20,071	19,461	39,686	166	79,385
Other underwriting-related fee income	-	-	(3,967)		(3,967)
Losses and LAE	13,822	13,070	15,993	208	43,092
Acq costs - stat	(17,290)	(9,395)	13,046	65	(13,574)
Change in DAC	(71)	1,389	(11,071)	(14)	(9,768)
Acquisition expenses – GAAP	(17,361)	(8,006)	1,975	51	(23,341)
Other operating expenses - GAAP	6,796	10,247	15,635	39	32,718
GAAP underwriting profit (loss)	16,814	4,150	2,116	(132)	22,949
GAAP ratios:					
Losses and LAE	68.9%	67.2%	40.3%	125.2%	54.3%
Acquisition expenses	-86.5%	-41.1%	5.0%	30.7%	-29.4%
Other operating expenses	33.9%	52.7%	49.4%	23.4%	46.2%
Combined ratio	16.2%	78.7%	94.7%	179.3%	71.1%

Footnote 1: Net earned premium includes revaluation FX G/L of €13.5m in respect of UPR. Excluding this adjustment, the net loss ratio was 65.4%. The equivalent adjustment in 2021 increased the loss ratio by 7%.

The equivalent table for year ended 31 December 2021 is provided in the following table.

<sup>&</sup>lt;sup>1</sup> Generally Accepted Accounting Practice in Ireland - accounting standards issued by the Financial Reporting Council of the UK, including Financial Reporting Standard 102 the Standard applicable in the UK and Republic of Ireland and promulgated by the Institute of Chartered Accountants in Ireland and companies Act 2014.

	Casualty	Property	Other Specialty	Marine &	Total YTD
	_	<u>-</u>	_	Other	_
	€'000	€'000	€'000	€'000	€'000
Gross premiums written	146,130	100,675	235,734	1,197	483,735
Net premiums written	13,815	11,532	23,087	112	48,545
Net premiums earned	13,651	7,511	19,830	154	41,145
Other underwriting-related fee income	-	-	(2,921)		(2,921)
Losses and LAE	12,138	7,498	6,052	92	25,781
Acquisition expenses – GAAP	(17,582)	(3,889)	1,278	65	(20,127)
Other operating expenses - GAAP	7,332	6,858	11,828	60	26,079
GAAP underwriting profit (loss)	11,762	(2,956)	(2,250)	(64)	6,492
GAAP net ratios:					_
Losses and LAE	88.9%	51.3%	30.5%	60.1%	62.7%
Acquisition expenses	-128.8%	-41.8%	6.4%	42.3%	-48.9%
Other operating expenses	53.7%	90.2%	74.4%	39.1%	70.5%
Combined ratio	13.8%	99.7%	111.3%	141.5%	84.2%

The above tables do not include items such as investment income, realized and unrealized gains and losses including those relating to foreign exchange.

#### Qualitative discussion - major lines of business

## 2022 to 2021 comparison

GWP for 2022 was €762.4m, prior to cessions to the Company's retrocessionaires. This is an increase of €279m or 57% compared to €484m in 2021. This increase is driven by several lines of business but most significant by C&S which increased GWP by €93m and Other Property which had a €68m increase in GWP. The growth achieved by C&S arose from niche opportunities in selected markets and becoming a more relevant market participant overall. Growth in Other Property was the result of continued hardening market conditions in this line of business, within both treaty and facultative areas. This growth was geographically spread but notable locations contributing to the increase premium income were South Africa and Australia. Casualty was up €30.5m, arising from a combination of new business written by the Company and from growth in the Company's renewal portfolio, primarily from rate increases. The increase in Other Specialty derived primarily from C&S, already discussed herein, Motor Quota Share and Agriculture lines of business. Agriculture premiums written grew €19.6m taking advantage of hardening conditions in various geographies.

The reported loss ratio improved in 2022 to 54.3% compared to 62.7% for 2021. Included in these respective ratios is the impact of an Irish GAAP adjustment requiring the revaluation of Unearned Premium Reserve (UPR) for foreign exchange rate changes. This adjustment increased Net Earned Premium by plus €13.5m (2021 - €5.2m decrease) to €79.4m. As most of the Company's retrocession purchased, including the 85% intercompany quota share agreement, are denominated in Euro this revaluation adjustment had a broadly similar impact on a gross and net basis. Excluding this accounting adjustment, the net loss ratio for 2022 was 65.4% (2021 – 55.7%).

Before the accounting adjustment referred to above, the net loss ratio increased by 9.7%. The impact of some large market loss events, most notably South African floods, Australian floods and Brazilian drought contributed to the increase in the loss ratio in 2022. These events impacted Other Property and Agriculture which sits within Other Specialty. Despite some attritional losses, other lines of business

performed in line with expectations. Marine is immaterial and its loss ratio disproportionately impacted by very small movements in losses.

The net underwriting profit for 2022 was €23.0m, excluding investment income and realized gains and losses and other non-underwriting items. The equivalent result for 2021 was a profit of €6.5m. The increase in the underwriting profit of €16.6m, is mainly explained by positive UPR revaluation movement of €13.5m, higher net overall earned premium arising from the growth in the business offset by an increase in operating expenses of €6.7m. Gross acquisition costs were in line with 2021 at 19.6% whilst net acquisition costs were lower driven by the growth in the business experienced and ceding commissions earned on the increase premium retroceded. The increase in operating expenses reflected several factors including growth in headcount both at the Company and in Group entities that provide support services and charges for same to the Company, and also increases in other discretionary elements of compensation.

#### Casualty

In the Casualty segment the Company's focus is on providing coverage to ceding company clients on third party liability products like motor, employers', general and/or professional liability, primarily on a treaty and more recently on a facultative basis. Our main markets are in Continental Europe, United Kingdom and Ireland. We are active in exploring other European territories as well.

The Casualty segment saw a 23% increase in GWP through both new business written by the Company, organic growth including in motor excess of loss and growth in the Facultative unit.

The overall performance across the Company's Casualty book is well within expectations.

### **Property**

The Company provides coverage for both personal lines and commercial property exposures and principally covers buildings, structures, equipment, and contents. On the treaty side we have seen further material growth with premium increased threefold from €62.9m to €117m. This growth was concentrated within a small number of geographies where the Company was able to leverage its entry to those locations in recent years. This was particularly the case in South Africa where written premium grew from €25.6m in 2021 to €64.5m in 2022. Growth in Israel, France, and Australia, along with South Africa, accounted for €104m of the treaty written premium in 2022. This growth was derived a through combination of factors namely the leveraging of favourable market conditions.

The Company's Property Facultative business is written by three teams based in London, Zurich and Copenhagen. The Company has seen an increased submission flow in this line due to continued increased demand from the specific needs of clients as well as following increased loss activity in certain markets. GWP for this unit grew from €26.0m in 2021 to €40.1m in 2022, growth which reflects the demand driver favourable market conditions. Risk selection remains critical to the underwriting of the Company. Much of this growth was driven by the reduced appetite of our clients which increased the demand for capacity from the market. Continued challenging attritional loss results, increased reinsurance cost and the impact of Covid-19 losses have contributed to these dynamics. The underwriting team remains focused on ensuring new business meets the Company's underwriting criteria.

The Company writes incidental Property Cat business and largely when related to other opportunities.

#### Other Specialty

Within the Other Specialty unit, the Company provides coverage to ceding company clients for A&H, Workers' Compensation Catastrophe, Agriculture, C&S and proportional Motor Liability. Geographically we run most of those lines on a highly diversified world-wide basis excluding the United States.

In C&S loss activity remained low with insurers reporting excellent loss ratios for underwriting years 2020 and 2021. The Company has been able to defend its portfolio and grow some of its core accounts, and develop new business with core relationships whilst staying true to its underwriting discipline. As a consequence of the factors discussed herein, particularly in relation to the new surety opportunities, GWP grew by €93m in 2022.

The Agriculture unit grew its GWP again in 2022, in comparison to 2021, increasing by €19.6m. During 2022 the Company was able to take advantage of hardening market conditions in specific sub-sectors of the agriculture (re)insurance market which experience capacity constraints (inter alia losses and market expansion). The performance of the Company's Agriculture book meets our expectations.

In A&H (also part of Other Specialty) GWP increased meaningfully by €31m in 2022. The growth came from new business secured, particularly in supplemental health and travel business, together with some organic growth in Company's existing A&H portfolio. Loss reserves associated with Covid-19 (i.e., travel, contingency) remain in line with those carried at the end of 2021. The supplemental health activity during 2022 continued to focus mainly on a small number of core relationships in Europe with an initiative with a new partner launched in France late in 2021 contributing to much of the growth seen in this product area. The combined A&H portfolio has performed as expected in 2022.

GWP in the Motor quota share business grew 340% to €41m GWP in 2022 (from €12m in 2021). This growth arose from our participation on a new quota share opportunity that incepted in 2022 and related to a motor market in a single geographic region where new capacity was welcome.

#### Marine and other

The Company has Marine activity in some legacy accounts. GWP in Marine and Other was just €1.7m in 2022.

## A.3 <u>Investment Performance</u>

ARE invests in a diversified portfolio of highly rated securities. Fixed income securities comprise most of the Company's investment assets. In addition to fixed income the Company also holds some short-term cash or cash equivalent securities, equity fund and an investment in a limited partnership which is valued using the equity method. The following table summarizes the invested assets of the Company at year ended 31 December 2022 and 2021.

	2022		2021	
	Amount €'000	% of Total	Amount €'000	% of Total
Bonds				
Government Bonds	485,215	74.6%	533,653	76.5%
Corporate Bonds	103,513	15.9%	67,713	9.7%
Asset Backed Securities	444	0.1%	767	0.1%
Subtotal	589,172	90.5%	602,133	86.3%
Short term investments				
Money Market Funds	754	0.1%	11,298	1.6%
Cash & Cash Equivalents	9,833	1.5%	35,739	5.1%
Subtotal	10,587	1.6%	47,037	6.7%
Equities				
Equity Funds	29,634	4.6%	36,673	5.3%
Equity method investment				
Limited Partnership Fund	21,351	3.3%	11,539	1.7%
Total	650,744	100.0%	697,382	100.0%

The components of net investment income included in the statement of income and expenses are as per the table below.

	2022	2021
Investment income	€′000	€′000
Interest income from:		
Government & Supranational Bonds	3,127	1,603
Corporate Bonds	1,819	1,055
Cash and Deposits	446	555
Total Interest Income	5,392	3,213
Investment return		
Foreign exchange gain/(losses) on investments	(25,255)	28,383
Unrealised gains/(losses) on investments	(66,982)	(18,391)
Realised gains/(losses)/ on investments	(6,452)	11,393
Income on investments valued under equity method	3,844	3,146
Total investment income & investment return	(87,453)	27,754
Investment expenses and charges	(1,253)	(1,259)
Net investment return	(88,706)	26,495

## A.4 Performance of other activities

The following table summarizes the profit and loss account in Euro for the non-technical account for year ended 31 December 2022 and year ended 31 December 2021.

	Year Ended 31/12/2022 €'000	Year Ended 31/12/2021 €'000
Balance on the technical account	(46,150)	15,880
Net investment return included in the non-technical account	(1,253)	(1,257)
Profit on ordinary activities before taxation	(47,403)	14,623
Tax on profit on ordinary activities	4,685	611
Profit on ordinary activities after taxation	(42,718)	15,234

There were no gains or losses recognised directly in equity.

There were no material other income or expenses during the year.

## A.5 Any other information

There is no other material information to report as of 31 December 2022.

## B.1 General information on the system of governance

#### **B.1.1** Overview

The Company is classified as Medium Low Risk under the CBI's PRISM rating framework and is subject to the CBI's Corporate Governance Requirements for Insurance Undertakings 2015 (the Code).

The Company's Board is responsible for overseeing, controlling and directing the activities of the Company. The Board retains primary responsibility for corporate governance within the Company at all times. Senior Management also plays an important role in ensuring effective governance.

The terms of reference of the Board require the Board be made up of at least five directors, the majority of whom must be non-executive directors or independent directors. At least two members of the Board must be independent non-executive directors.

The Board as at 31 December 2022 is as follows:

- Ian Britchfield, Chair (INED, Chair of the Board and Risk Committee);
- Gerald König (INED, Audit committee chair, Risk committee member);
- Anthony Asquith (INED, Risk committee member, Audit committee member);
- Soren Scheuer (NED, Risk committee member);
- Jason Kittinger (NED, Audit committee member) until December 2022;
- Deirdre Casey (NED, Audit committee member) from December 2022; and
- Michael Hammer, CEO (Executive Director, Risk committee member)

The company secretary is Mark Nolan.

The presence of independent non-executive directors ensures that there is an appropriate element of independent challenge and oversight.

The Board is responsible for overseeing the business of the Company and supervising management. The Board sets the standards of conduct of the Company, provides direction and oversight, and promotes a culture of integrity. While the Board delegates certain functions to Sub-Committees and Management, this does not absolve the Directors of their responsibility for the Company.

The Board operates under agreed terms of reference and has the following key responsibilities:

- To comply with any obligations for the Board prescribed by the Code, the Companies Acts 2014 and all other rules, regulation, guidelines and laws applicable;
- The effective, prudent and ethical oversight of the Company;
- Setting the business strategy for the Company; and
- Ensuring that the Company complies with its constitution as well as relevant legal, regulatory, and governance requirements.

The Board reserves the following matters specifically to the Board unless, where permitted by applicable Irish law and regulatory requirements, such matters are expressly delegated in writing to management, the Audit Committee, the Risk Committee of the Company, or otherwise. These matters are also subject, where appropriate, to the direction/decision of the shareholder.

- All matters prescribed as being specifically reserved to the Board by the Company's Memorandum and Articles of Association, company law, and regulatory requirements;
- Appointment of Members of the Board, subject to regulatory approval;
- Approval of minutes of meetings of the Board and acknowledgement of the content of any minutes of any Committee of the Board or management/operational committee;
- Approval or ratification of any recommendation from or action taken by management or any Committee of the Board or management/operational committee, to the extent that any such recommendation or action requires approval or ratification;
- Recommendation and approval of distributions or dividends to the shareholders;
- Approval of Annual Financial Statements and Regulatory Returns, including approval of content of, and signing, the annual directors' compliance certificate and the annual compliance statement with respect to the Code;
- Appointment of Auditors;
- Appointment of Bankers and/or Investment Managers or Advisors;
- Approval of any changes in the structure of the Board;
- Approval of the business plan, including but not limited to corporate strategy, goals and structure;
- Establishment, appointment to and/or dissolution of, as the case may be, Committees of the Board and management/operational committees, including prescribing and approving charters and/or terms of reference for such committees;
- Determining the Risk Appetite of the Company;
- Self-assessment of the Board, including in relation to composition, performance, conflicts of interest and any other matter specified in the Code. In relation to performance, the Board shall document the fact and results of its review;
- Waiver of any actual or apparent conflict of interest, if legally appropriate, involving the Company;
- Final approval of litigation or arbitration activities, including compromises and settlements of disputed litigation claims (other than ordinary course insurance claims);
- Approval of the removal from office of any head of a Control Function as defined in the Code;
- Dealings with (including disposal or acquisition of, or change of use of) any material asset of the Company;
- Approval of any appointments to Executive Management;
- Approval of matters outside of Company Policies (e.g., limits, products, investments);
- Approval of material agreements; and
- Any other matters not delegated to management or otherwise delegated by the Board.

The Board has an Audit Committee and a Risk Committee. Both are governed by their respective Terms of Reference.

The duties of the Audit Committee are:

- to liaise with the external and internal auditor particularly in relation to their audit findings;
- to oversee the relationship with the external auditors;
- to review the integrity of the Company's financial statements and to ensure that they give a "true and fair view" of the financial status of the Company;

- to review any financial announcements and reports and to recommend to the Board whether to approve the Company's annual accounts;
- to assess auditor independence and the effectiveness of the audit process;
- to monitor the effectiveness and adequacy of the Company's internal control, internal audit and IT systems;
- to review all reports on the Company from the auditors and management's responsiveness;
- to review and assess the annual audit plan including adequacy of resources and ensure that it is consistent with the scope of the audit engagement;
- to check quarterly the developments under the Annual Compliance Plan (for avoidance of doubt the other Compliance activities, such as training, reporting, advising and policies are overseen by the Risk Committee as part of the Annual Compliance Plan) and report to the Risk Committee
- to ensure the Compliance function has adequate resources and independence; and
- to review and challenge, where necessary:
  - o the consistency of, and any changes to, accounting policies;
  - the methods used to account for significant or unusual transactions where different approaches are possible; and
  - whether the Company has followed appropriate accounting standards and made appropriate estimates and judgments, taking into account the views of the external auditor.

## The duties of the Risk Committee are:

- to liaise at least quarterly with the Chief Risk Officer to discuss the quarterly Risk report and other matters under these Terms of Reference;
- to oversee the risk management function and to check quarterly the developments under the Annual Risk Plan;
- to review updated or new Risk Policies and make a recommendation to the Board;
- to review the Annual Plan for the Risk Function including a review of adequacy of resources;
- to review at least annually the Risk Management Framework and advise the Board accordingly;
- to ensure that the risk appetite is clearly articulated and reflected within the Risk Appetite Statement and that the Risk Appetite Statement is reviewed at least annually;
- to review at least annually the Risk Register and advise the Board accordingly;
- to review quarterly the Risk Matrix and advise the Board on the current risk exposures;
- to keep under review the Company's overall risk assessment processes ensuring both qualitative and quantitative metrics are used;
- to review the Company's capability to identify and manage new risk types;
- to advise the Board, before a decision is taken to proceed with a proposed strategic transactions including acquisitions or disposals, on risk aspects of such transaction(s) and any implications for the risk appetite and tolerance of the Company;
- to review reports on any material breaches of risk limits and the adequacy of proposed action;
- to ensure the Risk Function has appropriate access to information to enable it to perform its function effectively;

- to ensure the Risk Function has adequate independence and unfettered access to the Board and Chair of the Risk Committee:
- to consider other risk management topics, as defined by the Board;
- to monitor the effectiveness and adequacy of the Company's risk management processes;
- to advise the Board on the effectiveness of strategies and policies with respect to maintaining, on an on-going basis, amounts, types and distribution of both internal capital and own funds adequate to cover the risks of the institution;
- to review, challenge and advise on the inputs to and outputs from the (at least) annual ORSA process and report;
- to oversee the Compliance management function in relation to its policies, advising, reporting and training activities and to check quarterly the developments under the Annual Compliance Plan;
   and
- to review updated or new Compliance and Governance Policies and make a recommendation to the Board.

## **B.1.2** Code of Business Conduct

The Company has adopted the Group Code of Business Conduct ("Ethics Code"), which describes our ethical principles for the conduct of our business. The full text of the Ethics Code and our Corporate Governance Guidelines are available on the Group's website located at <a href="https://www.archgroup.com">www.archgroup.com</a>.

## **B.1.3** Independent Control Functions

The Company has in place four key independent control functions as required under the Corporate Governance Requirements for Insurance Undertakings 2015. These are:

- Risk Management (See Section B3)
- Compliance (See Section B4.2)
- Actuarial (see Section B6)
- Internal Audit (see Section B5)

These functions are responsible for providing oversight of and challenge to the business and for providing assurance to the Board in relation to the Company's control framework. Each function has the necessary authority, resources and operational independence to meet their responsibilities.

#### **B.1.4** Material Changes

There have been no material changes in the memberships of the Board and Committees over the period.

## **B.1.5** Remuneration Policy and Practices

The ACGL Compensation Committee, in its capacity as a committee of the ACGL Board, has overall responsibility for approving and evaluating, and making recommendations to the Board regarding compensation plans, policies and programs of the Company for senior executives, as well as compensation parameters for all other employees of the Company and its controlled subsidiaries.

The Company has a Remuneration Policy in place which is guided by principles which are embedded in the Company's risk management framework and in Code of Ethics. The Code of Ethics embodies the Group's goal of promoting an organisational culture that encourages the highest standards of ethical business conduct. The Remuneration Policy follows compensation parameters established and approved by ACGL Compensation Committee.

The Board of the Company is responsible for the implementation and administration of the Policy. It is not deemed appropriate or proportionate, given the scale of the business and the governance structure in place in Ireland and within the Arch Group, to appoint a Remuneration Committee. At least annually, the Risk Committee of the Company will review the Policy against the Company's risk framework and provide recommendations to the Board. The Board will review the Risk Committee's recommendations and ultimately approve the Policy for implementation if appropriate.

The CEO is responsible for reporting to the Board on the implementation and operation of this Policy, and consequent controls and processes. The Head Of Compliance ("HOC") is responsible for coordinating the review of the Policy at least on an annual basis as part of the Compliance Plan. The HOC and CEO will present recommendations for changes to the Policy to the Risk Committee.

The CEO will monitor the implementation of the Policy, then conferring with the Group Human Resources staff, confirm that the Policy is being implemented appropriately. Reasonable evidence of the implementation shall be provided to the HOC.

Responsibility for the determination of fixed salary levels rests with the CEO. For departmental staff, consultation is undertaken with department heads. The remuneration of the CEO is set at the Group level.

The principal features of our compensation programs and policies are summarized below.

## **Key Principles**

Remuneration decisions are meant to encourage employees to meet the strategic aims and objectives of the Company within a framework of prudent and effective risk management and system of internal controls. Remuneration decisions should also take into account financial and non-financial considerations, as well as an employee's functions, responsibilities and experience.

## **Material Risk Takers**

With respect to Material Risk Takers, who are defined as those employees who are permitted to commit or bind the Company to reinsurance transactions and to accept risk on behalf of the Company, the Policy also embodies the Group's guiding principles to emphasize long-term compensation tied to Group performance in order to mitigate excessive risk-taking. Arch philosophy requires exercise of judgment in making compensation decisions for employees after reviewing the Group's and Company's overall performance and long-term interests and evaluating an employee's performance during the year against established objectives, leadership qualities, scope of responsibilities and current compensation. Specific factors affecting compensation decisions include key financial metrics, such as growth in book value, return on capital, after-tax operating income, combined ratio and investment performance, as well as achieving strategic objectives and supporting Arch's values by promoting a culture of integrity through compliance with law and its ethic policies. Fixed (base salary) and variable (bonus) components of remuneration may be adjusted upwards or downwards based on these considerations. The Group can modify or terminate elements of the compensation program for Material Risk Takers which create a fully flexible bonus policy, including the possibility of no pay-out of the variable cash component and no issuance of new equity awards. In addition, senior management, who are not within the definition of Risk Takers, also participate in this long-term compensation plans linked to Group performance.

#### Formula Approach

Material Risk Takers and some senior non-Material Risk Takers who perform an underwriting support function and who are eligible to receive cash bonuses will be granted them based on a "Formula Approach", which is determined by ACGL. Under the Formula Approach, a bonus pool is established for each business segment based on underwriting performance during a given underwriting year. Further, individual performance is factored using a modifier to the target which becomes the basis for future payouts for that specific underwriting year. For each underwriting year, the bonus pool will be recalculated annually as actual underwriting results emerge, and any resultant payments will be made to the employees over a 10-year development period. A deferral period of three years is in place for a substantial portion of the bonus in that the bonus is paid out over ten years. The Group adopts this approach because it believes that much of its business requires multiple years to determine whether the business written has been successful (in terms of return on capital). The Group believes that making payments to employees over a period of years as actual results become known effectively aligns pay with performance. Thus, performance-based remuneration is awarded in a manner which promotes sound risk management, does not induce excessive risk-taking and encourages the highest standards of ethical business conduct.

#### **Risk Management**

We believe our approach to evaluation of performance and the design of our compensation programs assists in mitigating excessive risk-taking that could harm our Company. We emphasize variable compensation that is tied to Company performance. For senior management, we emphasize long-term compensation that vests over a multi-year period. Furthermore, and as discussed above, the Formula Approach is based on underwriting performance during a given underwriting year. For each underwriting year, the bonus pool will be recalculated annually as actual underwriting results emerge, and any resultant payments will be made to the participants over a 10-year development period. Since much of our business requires multiple years to determine whether we have been successful in our assessment of risk, we have structured our plan in this manner so that incentive payments are made to employees as actual results become known. In addition, senior management is subject to our clawback policy and share ownership guidelines with hedging/pledging restrictions.

## **B.1.6** Supplementary Pension / Early Retirement Schemes

The Company operates a defined contribution plan for certain employees. A defined contribution plan is a pension plan under which the Company pays fixed contributions into a separate entity and has no legal or constructive obligation to pay further contributions or to make direct benefit payments to employees if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. The assets of the plan are held separately from the Company in independently administered funds. The contributions to the defined contribution plan are recognised as an expense when they are due. Amounts not paid are shown in accruals in the balance sheet.

#### **B.1.7** Material Transactions

The Company received a capital contribution of €22.7m from it's parent company which was invested in its subsidiary Arch Insurance UK to support the continued growth of that business.

#### **B.2** Fit and proper requirements

## **B.2.1** Fit and Proper Process

The Company's Fitness & Probity ("F&P") policy sets out the requirements to ensure that employees meet the fit and proper standards, both on entry and throughout their employment at the Company. The CEO is responsible for implementing this policy, while the HOC is responsible for providing advice, implementing a monitoring program and reviewing the policy at least annually.

The HOC identifies and maintains a record of Pre-Approved Controlled Function ("PCF") and Controlled Function ("CF") holders. Before the Company can appoint a person to a PCF, the CBI must have approved the appointment in writing.

The F&P policy sets out a number of steps that must be carried out before proposal of a PCF to the CBI. These include, but are not limited to:

- a competency interview to establish evidence of the required competencies;
- a full chronological interview to establish patterns and trends in behaviour that should indicate integrity and competency;
- a full and thorough screening by an independent third-party company with a recognised reputation for pre-employment screening, where necessary; and
- pre-employment screening including identity verification, credit and bankruptcy checks, selfcertification on conflicts of interests, directorship checks, education and professional qualifications validation, employment reference checks, compliance and regulatory checks.

#### **B.2.2** Professional Qualifications, Skills and Expertise

The Company ensures that all persons who hold key positions or functions are fit to provide sound and prudent management through their professional qualifications, knowledge and experience and are proper by being of good repute and integrity.

As described above, the F&P policy sets out the due diligence that must be performed before a candidate is proposed to the CBI to a PCF role, or appointed to a senior management position. The process aims to ensure that key function holders and decision makers have the requisite employment experience, technical skills, professional qualifications and key competencies to perform their duties to the highest standard.

All employees are monitored on an on-going basis through a formal performance appraisal process and continuing professional development. Specific requirements include:

- Appraisal meetings are conducted in the third month of employment;
- The appraisal meeting focuses on development by reviewing the employee against a set of competencies specific to their role and on setting objectives for the next year and measurement of goals during the first three months of employment. Competency also is reviewed at this meeting;
- Formal appraisal meetings are held annually to ensure that staff continues to meet their goals and to set new objectives for the year ahead;
- Appraisal meetings and development requirements are documented and training needs are actioned via the appropriate training methods;

- Employees are encouraged to maintain an on-going record of their continuous professional development/training;
- Employees are required to attend a minimum level of training courses and maintain a minimum standard of competency. Examples of areas covered by on-going training are work specific roles; general insurance; legal issues and regulations; and
- Employees also are required to complete in-house training, including code of conduct training, anti-harassment training and anti-money laundering.

## B.3 Risk management system including the own risk and solvency assessment

## **B.3.1** Chief Risk Officer

The Board has approved the CRO, who is responsible for the Risk Management Function. The Board has approved a Risk Management Charter and terms of reference for the CRO / Risk Management Function and reviews the terms of reference annually. The Risk Committee has approved the annual risk plan and reviews the plan annually.

The Risk Management Function is defined as a "Key Function" in Solvency II. The CRO has responsibility for the Risk Management Function and is the Key Function Holder for Risk Management.

The CRO's primary responsibility is to the Board, and reports to the Board periodically with direct access to the Chair of the Board. The CRO also reports to the Risk Committee, at least quarterly. The CRO is a member of the Executive Management Meeting.

The Risk Management Function and CRO carry out the following duties:

- ensure that ARE has and maintains effective processes to identify, monitor, manage and report on the risks to which ARE is or might be exposed;
- measure and assess the controls of material risks;
- implement the risk management framework and risk policies;
- prepare a regular risk report including a view of all current and future material risks;
- provide comprehensive and timely information on ARE's material risks which enables management and the Board to understand the overall risk profile;
- be the central point for risk reporting;
- maintain a Risk Function calendar of activities;
- report on the effectiveness of the risk management system;
- provide advice on risk management to all Stakeholders;
- provide education and training on risk matters to colleagues and staff in related companies;
- promote a strong risk culture;
- co-ordinate the annual refresh of the risk policies;
- maintain the risk register;
- lead the ORSA process; and
- facilitate the setting of the risk appetite by the Board.

#### **B.3.2** Risk Management Process and Procedures

As described above, the CRO produces regular risk reports, including the quarterly CRO report. This reporting aims to provide the Board, Risk and Audit Committees with sufficient oversight of the Risk Management Framework and the risks to which the company is exposed.

The ORSA process is carried out throughout the year, which facilitates integration with decision making, culminating in the annual ORSA report which is owned and shaped by the Board.

The Company has a Risk Management Framework in place which is designed to support the Company's decision-making procedures by providing consistent, reliable and timely risk information and protecting capital from risks that exceed established risk tolerances.

The following narrative provides an overview of the Risk Management Framework ("RMF"), which sets out the Company's methodology for identifying, measuring, managing and reporting on the key risks affecting ARE. It outlines ARE's approach to risk identification and assessment and provides an overview of ARE's risk appetite and tolerance for each of the following major risks:

- Underwriting Risk;
- Market risk;
- Counterparty credit risk; and
- Operational, including governance, regulatory, business/strategic, investor relations (reputational), rating agency and outsourcing risks.

The RMF includes details of the Company's:

- Risk philosophy and policies to address the material risks confronting the Company; and
- Compliance approach and procedures to control and or mitigate these risks.

The RMF follows the Three Lines of Defence model, and fits into the overall governance structure as follows:

## BOARD

#### First Line of Defense

Risk/Process Owners

**Business Unit Directors** 

Actuarial Function

#### Second Line of Defense

Risk Management Function

Compliance Function

Executive team

#### Third Line of Defense

Internal Audit

SOX Compliance

Audit Committee

Risk Committee

## RISK MANAGEMENT FRAMEWORK





## OWN RISK AND SOLVENCY ASSESSMENT

The actions and policies implemented to meet the Company's business management and regulatory obligations form the core of this framework. The Company has adopted a holistic approach to risk management by analysing risk from both a top-down and bottom-up perspective.

#### Risk Identification and Assessment

The Risk Committee of the Board oversee the top-down and bottom-up review of the Company's risks. Given the nature and scale of the Company, the committee considers underwriting, investments and operational risks within the scope of the assessment. The CRO assists the committee in the identification and assessment of all key risks.

The CRO is responsible for maintaining the Risk Register and continually reviewing and challenging risk assessments, including the impact of emerging risks and significant business developments. Board approval is required for any new high-level risks or change in inherent / residual designations.

## Risk Monitoring and Control

ARE's RMF requires risk owners to monitor key risks on a continuous basis. The highest residual risks are actively managed by the Risk Committee. The remaining risks are managed and monitored at a process level by the risk owners and/or CRO.

Risk owners have ultimate responsibility for the day-to-day management of each designated risk, reporting to the CRO on the satisfactory management and control of the risk and timely escalation of significant issues that may arise in relation to that risk.

The CRO is responsible for overseeing the monitoring of all risks across the business and for communicating to the relevant risk owners if he becomes aware of issues, or potential and actual breaches of risk appetite, relevant to the assigned risks.

A key element of these monitoring activities is the evaluation of the Company's position relative to risk tolerances and limits approved by the Board.

## **Risk Reporting**

Quarterly, the CRO compiles the results of the key risk review process into a report to the Risk Committee for review and discussion at their quarterly meeting. The report includes:

- An overview of selected key risks (e.g., Underwriting, Market, Credit);
- Changes in the rating of high-level risks in the Risk Register;
- A risk dashboard that depicts the status of risk limit and tolerance metrics;
- Summary of largest exposures and concentration risks; and
- Reinsurance arrangements, including outstanding and uncollectible recoveries.

If necessary, risk management matters reviewed at the Risk Committee meeting are presented for discussion by the Board. The CRO is responsible for immediately escalating any significant risk matters to ARE executive management, the Risk Committee and/or the Board for approval of the required remediation.

## **B.3.3** Implementation and Integration of ORSA

The Company believes an integrated approach to developing, measuring and reporting its ORSA is an integral part of the RMF. The ORSA process provides the link between the Company's risk profile, its Board-approved risk appetite including approved risk tolerances and limits, its business strategy and its overall solvency requirements.

The ORSA is the entirety of the processes and procedures employed to identify, assess, monitor, manage, and report the short- and long-term risks the Company faces – or may face – and to determine the capital necessary to ensure that overall solvency needs are met at all times. The ORSA also makes the link between actual reported results and the capital assessment.

The ORSA process and reporting are integral parts of ARE's business strategy, tailored specifically to fit into ARE's organisational structure and risk management system with the appropriate techniques in place to assess its overall solvency needs, taking into consideration the nature, scale and complexity of the risks inherent in the business.

The Company also takes the results of the ORSA into account for its system of governance, including long-term capital management, business planning and new product development. It also contributes to various strategic decision-making including how best to optimise capital management, establishing the most appropriate premium levels and deciding whether to retain or transfer risks.

The ORSA is the basis for risk reporting to the Board and its committees and acts as a mechanism to embed the Risk Management Framework within the Company's decision-making processes and operations. The Board has delegated responsibility for supervision and oversight of the ORSA to the Risk Committee. This oversight includes regular reviews of the ORSA process and output.

An ORSA Report is produced at least annually and the results of each assessment are reported to the Board. The Board actively participates in the ORSA process by steering how the assessment is performed and challenging its results, including suggesting and challenging stress scenarios. This assessment is also taken into account when formulating strategic decisions for the Company.

## **B.3.4** Performance, Documentation and Review of the ORSA

A full ORSA cycle is performed at least annually and reported to the Risk Committee of the Board.

The ORSA process is a circular process that relies on key elements of the business:

- The Board outputs Strategy / Capital Management Plan / The Board Risk Appetite/ORSA Policy;
- Business planning providing the basis for the base case projections;
- The Solvency II Pillar I standard formula 5 year outputs & base assumptions used;
- The Risk Committee who review, challenge & approve the test scenarios, and ORSA process and output;
- The Actuarial Function who quantify technical provisions and provide other input into the Pillar I model;
- The Risk Function and Management who quantify the Pillar I capital requirements, assess the
  outputs and prepare the reports;
- The Risk Committee & Board who provide an assessment of the output and resultant capital, strategy & risk appetite review; and
- ORSA Reporting to all stakeholders.

The Key Activities in the ORSA Process are:

- Strategy & Planning;
- Pillar I base outputs and assumptions;
- Risk identification & assessment;
- Scenario setting;
- Scenario testing through the Pillar I model & production of test output;
- Review of test output & report preparation; and
- Risk Committee & Board review & reporting.

Each run of the ORSA process will be appropriately documented to evidence each of its constituent parts, and this record will be retained for any later scrutiny.

The documentation shall contain:

- A summary of the Board strategy for the Company;
- The Risk Appetite Statement;
- The Pillar I standard assumptions & output;
- The schedule of scenarios to be tested, cross-referenced to the Risk categories in the Board's risk appetite, and quantification of deviations from the base assumptions;

- The scenario test results;
- The ORSA report;
- Any Audit and Risk Committee Minutes relating to scrutiny & challenge of the ORSA process & outputs;
- Any Board minutes relating to ORSA output review & challenge resultant strategy decisions and risk appetite review; and
- A record of the report to the CBI.

### B.3.5 Relationship between the ORSA, Solvency Needs, and Capital and Risk Management Systems

The Company has both a Capital Management Policy and Capital Management Plan in place. The Risk Management Function is responsible for developing and maintaining the Capital Management Plan. The Risk Committee reviews and monitors the plan and presents it to the Board for approval. The Audit Committee is responsible for monitoring the alignment of the investment strategy with the plan.

The Capital Management Plan incorporates the output from the ORSA and associated reporting. The plan also sets out triggers for corrective capital actions relative to the Company's Solvency Ratios, both in terms of SCR and MCR.

ARE's capital planning process aims to be dynamic and forward-looking in relation to ARE's risk profile and shall take into account the output from ARE's risk management activities and the ORSA process and associated reporting as part of capital planning activities.

As such, capital planning activities take into account any current or anticipated changes in ARE's risk profile, such as those reflected in its business plan, and forecasting the related impact on capital. In addition, as part of its capital planning, the Company integrates projected capital needs with its business planning and financial forecasting processes.

The Capital Management Plan identifies a number of potential sources of capital and associated corrective actions that may be utilised to restore sufficient capitalisation, depending on the severity of the capital requirements placed upon ARE.

When considering the sources of capital and corrective actions, ARE will have regard to the Solvency II Own Fund requirements.

Any material changes in the underlying risks, such as changes in business mix, reinsurance strategy and investment strategy, are modelled for potential impact upon ARE's capital requirements. The result of this process is to ensure that all material risks feed into the capital requirements analysis, and in some cases also trigger further investigation through stress testing.

#### **B.3.6** Approval Process

The Company records the actual performance of the overall capital assessment and the assessment of any deviations in its risk profile from the assumptions underlying the capital requirements analysis to a level of detail that enables a third party to evaluate the assessments performed.

The CRO prepares a quarterly report for the Risk Committee covering risk management in general, including relevant ORSA topics, for discussion in the Risk Committee meetings. The Risk Register is presented to the Risk Committee on an annual basis for review, followed by Board approval. Any material changes in the risk management strategy, policies, processes, procedures and/or capital requirements analysis are presented to the Board for approval.

The ORSA policy and the ORSA report are reviewed by the Risk Committee and recommended to the Board for approval.

## **B.4** Internal control system

#### **B.4.1** Internal Control System

ARE maintains an effective internal control system, which includes administrative and accounting procedures, an internal control framework, appropriate reporting arrangements and a compliance function.

The Board is responsible for monitoring the establishment and maintenance of the system of controls used to assess and manage exposure to all areas of risk. The objectives of these controls are to ensure that ARE's risk strategy is maintained and risk remains within the appetite and tolerances set by the Board.

ARE is part of Group-wide compliance activities, including management's assessment to confirm the design and operating effectiveness of internal controls over financial reporting and the identification and testing of key internal controls, including any required remediation.

The Board has delegated management and oversight of certain controls to appropriate forums within the Group. ARE's internal control framework provides an appropriate level of reporting on the control environment to the Board.

Controls are detailed in the Risk Register, which associates elements within the category of risk to one or more mitigating controls. ARE's internal control framework includes reviews of both the design and effectiveness of key controls, with results of this periodic evaluation regularly reported to the Board. Key controls are verified using a compliance monitoring system and the output is reported to the Audit Committee Chair.

The Group's Sarbanes-Oxley ("SOX") compliance function's testing of internal control over financial reporting ("ICFR") is a major element of the Company's monitoring activities. The focus of testing is to provide auditable evidence regarding the design and operating effectiveness of ICFR. A major component of this process is the identification, tracking and disposition of internal control deficiencies that are assessed individually and in the aggregate. The results of the testing are continually communicated to stakeholders who include senior management, process/control owners and the Group Audit Committee.

#### **B.4.2** Compliance Function

## <u>Implementation of the Compliance Function</u>

The Board has approved a HOC who is responsible for the Compliance Function. In addition, the Board approved a Compliance Function Terms of Reference and a Compliance Plan which have to be reviewed on an annual basis. Changes have to be approved by the ARE Board.

The Compliance Function Terms of Reference contains, among others, Mission Statement, Guiding Principles, Authority, Accountability, Activities, Planning and Reporting of the Compliance Function.

While the Board retains primary responsibility for compliance and governance within ARE at all times, senior management plays an important part in ensuring effective governance and compliance and hence is responsible for operating effective oversight consistent with Board policy. The role of the Compliance Function is to assist and advise the Board and management with their responsibilities. In addition, senior management and all staff members are responsible for their own regulated activities and for complying with relevant rules, legislation, standards, contracts, policies and procedures relevant to their work.

The high-level goals of the Compliance Function are:

- To ensure that a proportionate compliance infrastructure is in place;
- To identify and manage Compliance risks;
- To implement a review and monitoring program; and
- To help the business to meet requirements with applicable legislation and regulation.

The HOC has to produce and submit an Annual Compliance Plan to the Board for approval. The Compliance Plan ensures that the Compliance Function's work has a focus with measurable output that is understood by and aligns with expectations of the business. It determines the actions that the Compliance Function needs to achieve in the next 12 months.

The Compliance Plan shall cover at least the following:

- Compliance Objectives;
- Compliance Resources;
- Provision of regulatory staff training;
- Revision of existing policies and procedures;
- Preparation of new policies and procedures;
- Monitoring details of a risk based monitoring review program; and
- Projects on-going and planned business or regulatory projects.

The HOC is required to make following internal reports:

- Quarterly to the Risk Committees;
- Monthly to the CEO;
- Promptly report any material or major compliance issues identified to the relevant person and the CEO; and
- Provide update to management team at the bi-weekly management call hosted by the CEO.

#### Independence and Authority

At ARE, the Compliance Function does not hold any other responsibilities besides Compliance. The HOC attends Committee and Board meetings and reports to the Audit and Risk Committee and the Board on all relevant matters. The HOC attends the Executive Management Meetings.

The Compliance Function is authorised to review all areas of the Company and has full, free, and unrestricted access to all Company activities, records, property and personnel. Compliance has full and direct access to ARE's Board and the authority to escalate matters to ACGL where required.

#### **B.5** Internal audit function

The purpose of Arch Capital Services LLC ("ACS") Internal Audit services function ("IA") is to provide independent, objective assurance and consulting services designed to add value and improve Arch Capital Group Limited's ("ACGL") and its subsidiaries' (including ARE) operations. The Company has a Head of Internal Audit (PCF-13) who is employed by ACS. As such, it is deemed by the Company that the internal audit function is effectively outsourced to ACS.

IA governs itself by adherence to the mandatory elements of The Institute of Internal Auditors ("IIA") International Professional Practices Framework, including the core principles for the Professional Practice

of Internal Auditing, the Code of Ethics, the International Standards for the Professional Practice of Internal Auditing, and the Definition of Internal Auditing.

An Annual Internal Audit Plan ("Audit Plan") is produced and submitted to the Company's Audit Committee prior to the start of the year to which the Audit Plan pertains. The Plan takes into consideration management's view of key and emerging risks, as well as IA's assessment of the Company's key and emerging risks and related controls and their linkage to historical and planned audits.

The Head of IA also coordinates activities, where possible, and considers relying upon the work of other internal and external assurance and consulting service providers as needed. IA may perform advisory and related client service activities, the nature and scope of which will be agreed with management, provided IA does not assume management responsibility.

IA maintains a comprehensive Charter which outlines key IA practices.

## **B.5.1** Maintenance of Independence

The Head of IA will ensure IA remains free from all conditions that threaten the ability of internal auditors to carry out their responsibilities in an unbiased manner, including matters of engagement selection, scope, procedures, frequency, timing, and report content. If the Head of IA determines that independence or objectivity may be impaired in fact or appearance, the details of the impairment will be disclosed to the appropriate parties.

Internal auditors will maintain an unbiased mental attitude that allows them to perform engagements objectively and in such a manner that they believe in their work product, that no quality compromises are made, and that they do not subordinate their judgment on engagement matters to others.

Internal auditors will have no direct operational responsibility or authority over any of the activities audited. Accordingly, internal auditors will not implement internal controls, develop procedures, install systems, prepare records, or engage in any other activity that may impair their judgment, including:

- Assessing specific operations for which they had responsibility within the previous year.
- Performing any operational duties for the Company or its affiliates.
- Initiating or approving transactions external to IA.
- Directing the activities of any Company employee not employed by IA, except to the extent that such employees have been appropriately assigned to engagement teams or to otherwise assist internal auditors.

#### **B.5.2** Process for Reviewing Internal Audit Policy

The Internal Audit policy is reviewed and updated in line with ACGL's IA Charter to reflect amendments that may be required as a result of Company specific legislative or regulatory changes. The review is carried out at least annually by the Head of Compliance as part of the Compliance Plan.

#### **B.6** Actuarial function

The Board has approved the Head of Actuarial Function ("HoAF"), who is responsible for the Actuarial Function. The Board has approved terms of reference for the Actuarial Function and reviews the terms of reference annually. The terms of reference state that the Actuarial Function must be free from influence from other functions and the Board.

The Board provides oversight to ensure the HoAF has adequate resources and authority to operate effectively.

The main activities of the Actuarial Function in a Solvency II environment shall include the requirements of the Solvency II Directive, the Society of Actuary in Ireland's Domestic Actuarial Regime and the CBI Guidance for (Re) Insurance Undertakings on the Head of Actuarial Function Role including:

- Coordinate the calculation of technical provisions;
- Ensure the appropriateness of the methodologies and underlying models used as well as the assumptions made in the calculation of technical provisions;
- Assess the sufficiency and quality of the data used in the calculation of technical provisions;
- Compare best estimates against experience;
- Inform the Board of the reliability and adequacy of the calculation of technical provisions;
- Oversee the calculation of technical provisions in the cases set out in the regulations;
- Express an opinion on the overall underwriting policy;
- Express an opinion on the adequacy of reinsurance arrangements;
- Contribute to the effective implementation of the risk management system;
- Provide an Actuarial Opinion on Technical Provisions;
- Provide Actuarial Report on Technical Provisions; and
- Express an opinion on each ORSA process.

On an annual basis the Head of Actuarial Function will prepare an Actuarial Opinion on Technical Provisions ("AOTP") and present the Actuarial Report on Technical Provisions ("ARTP") to the Board. The ARTP will be prepared in line with relevant regulatory and Actuarial Standards of Practice.

The Actuarial Function comprises experienced, fully qualified, individuals with in-depth knowledge of actuarial and financial mathematics. The function is staffed appropriately given the nature, scale and complexity of the risks inherent in the integrated operations.

ACGL's Chief Actuary oversees actuarial policies throughout the Group, as well as development of Group-wide actuarial techniques and education. This individual provides an independent assessment of the Group's reserves to the ACGL Audit Committee each quarter.

## **B.7** Outsourcing

## **B.7.1** Outsourcing Policy

ARE defines outsourcing as contracting out part or all of an internal business process to a third-party provider (either outside or inside the Arch Group of companies). In this regard ARE may use the external service provider's processes and controls to perform the agreed upon services. However, ARE will retain all decision making and ultimate responsibility over the business function and maintain the appropriate monitoring mechanisms to ensure adherence to a service level agreement.

The Company has an Outsourcing Policy in place which sets out the following:

- The definition of outsourcing;
- Responsibility for implementation and operation of the policy and consequent controls and processes;
- The criteria for outsourcing;
- The approval process;
- Contract and legal requirements;
- Risk assessment and risk mitigation measures; and
- Monitoring and on-going requirements.

Key functions that have been outsourced (within the Arch Group) include:

- Investment Management Services (to Arch Investment Management Ltd.); and
- Head of Internal Audit (to Director of Internal Audit Services at ACSI).

## **B.8** Assessment

Given the nature, scale and complexity of the risks inherent in our business, we conclude that the Company's system of governance is adequate and appropriate.

## **B.9** Any other information

No other material information to report as of 31 December 2022.

#### **Overview**

ARE's risk appetite framework provides an expression of the level of risk the Company is willing to accept in pursuit of its strategic objectives. The risk appetite framework provides quantitative and qualitative statements which are used to define the general attitude within the organization towards the desired level of risk. It not only supports the Company's risk management framework, it also enables ARE to make informed business decisions having regard to the key risks to which it may be exposed by such a decision.

In general, ARE has an appetite for insurance (underwriting) risk and a tolerance for other forms of risk. The risk philosophy of ARE encompasses all major risks and focuses on attaining the following business objectives:

- Underwrite business that meets agreed targeted returns;
- Underwrite business with selected cedants;
- Underwrite only carefully selected business lines;
- Manage underwriting volumes in line with the business cycle; and
- Limit the downside risk such that the Company maintains a sufficient solvency margin.

The following table shows the composition by sub-module of the SCR as at 31 December 2022, along with the composition as at 31 December 2021 for comparison purposes.

Risk Category	Description	Allocated % of	Allocated % of
		SCR as at	SCR as at
		31-Dec-22	31-Dec-21
Underwriting Risk	Risk of losses from business already written or planned to be written over the next year	18.7%	19.7%
Market Risk	Risk of losses from market movements, including exchange rates and investment returns	69.2%	68.7%
Credit Risk	Risk of losses from counterparty defaults, including reinsurers and other counterparties	7.6%	6.3%
Operational Risk	Risk of operational losses	4.5%	5.3%

## C.1 Underwriting risk

#### C.1.1 Key Underwriting Risks

Underwriting risk refers to the risk of loss, or of adverse change in the value of insurance/reinsurance liabilities, due to inadequate pricing or risk quantification assumptions, which includes the fluctuations in the timing, frequency and severity of insured events. At a risk policy level, we consider underwriting risk is linked to reserving risk. Reserving risk refers to the risk of loss, or of adverse change in the value of insurance liabilities, due to inadequate reserving assumptions, which includes the fluctuations in the timing, frequency and severity of insured events.

As already mentioned in <u>Section A</u>, the reinsurance industry remains competitive in many parts but profits from a firming in primary rate and conditions in select places are continuing. Competition is prevailing, as the current market is not stressed enough and new capacity entered into 2022 to benefit from improvements in market conditions. Furthermore, the nature and breadth of the business we write means we are exposed to regulatory, legislative and fiscal changes, economic factors and changes in behaviour, as well as catastrophe events.

The resulting key underwriting and reserving risks identified by management are:

- Reserve Risk: The risk of loss, or adverse change, in the value of insurance liabilities due to the occurrence, amount, and timing of claims, inadequate pricing and provisioning assumptions;
- Pricing Risk: The risk of loss due to inadequate pricing of business pre-claim; and
- Catastrophic Risk: The risk of loss from infrequent high severity claims from natural or man-made disasters.

#### **C.1.2** Material Risk Concentrations

An identified risk to the Company is an inappropriate concentration of underwriting risks, through over-exposure to a particular geographic region, line of business / peril or cedant. The risk is monitored in the Risk Register and is managed through a number of controls, including the setting of exposure limits, modelling of catastrophe exposure and quarterly measurement and reporting of accumulations. C&S concentrations are limited at the portfolio level through monitoring of the maximum probable maximum loss per counterparty group. Single Realistic Disaster Scenario events at a 1 in-250-year return period are limited to less than 25% of shareholders' equity (net of expected reinsurance recoverables). After controls, the risk is considered low impact; therefore, there is not considered to be material underwriting risk concentration.

#### **C.1.3** Underwriting Risk Mitigations

ARE purchases Excess of Loss retrocession protection on particular programmes to mitigate the impact of catastrophic claims and/or to manage accumulations of risk. In addition, both inter-company and external Quota Share reinsurance is in place to mitigate the impact of attritional losses. An inter-company Stop Loss agreement is also in place to help protect the overall underwriting result against deterioration beyond a pre-determined level.

In addition, underwriting risk is further mitigated through a number of controls and practices, which include the following:

- Business performance is monitored regularly, including consideration of market factors, pricing trends and strategic challenges;
- Actual performance is compared against expected each quarter;
- Treaties are subject to the four-eye review principle peer underwriter review ensures that guidelines are being adhered to;
- Pricing is processed by a pricing actuary, independent from the underwriting function;
- ARL's Property Cat modelling group assist with the validation of the models and assumptions used for pricing and to analyse Property Cat exposures;

- Audits are performed in respect of selected cedents/contracts periodically to review underwriting standards and claims files to ensure accuracy of cedents reporting to ARE and adherence to treaty terms and conditions:
- Bi-annual European underwriting meetings occur in ARE, attended by all key underwriting staff, senior executives from ARE and representatives from ARL to review risk, claims and underwriting performance at contract level, movements and aggregation. Market conditions are also discussed;
- Quarterly Change Report ("QCR") meetings are held between the Underwriting, Finance and Actuarial teams to review development of treaties relative to expectations;
- A quarterly IBNR memo from the HoAF documents known issues and underlying assumptions around loss reserves and is sent out to Executive Management; and
- An independent actuarial firm provide an annual review of ARE reserves.

## C.1.4 Stress and Sensitivity Testing

Stress and scenario testing is carried out as part of the ORSA process, which is conducted at least annually. These tests consider moderate as well as extreme but plausible stresses and assess the impact on ARE's capital position.

We considered a number of scenarios in the ORSA which aim to reflect the underwriting and reserving risk to which the company is exposed.

Numerous Realistic Disaster Scenarios ("RDS") were devised in conjunction with underwriting teams across the various lines of business; these represent very adverse scenarios to which the company could be exposed. We also devised a scenario in which reserves are not adequate to meet the liabilities that arise, and therefore must be increased by 20% for short development business and 10% each projected year for long development business. The projected SCR and Own Funds were then calculated under each of these scenarios, allowing the Company to assess the capital impact and profit metric of each scenario.

Due to the Company's capital strength, while the stresses showed deterioration in the Company's capital position, none of the modelled scenarios were considered likely to result in a breach of the SCR. The Company's underwriting risk profile is therefore considered to be resilient to most shocks.

#### C.2 Market risk

#### C.2.1 Key Market Risks

Market Risk is the risk of changes in income or values of assets arising from fluctuations in political and economic variables (systemic), including interest rates, currency exchange rates, equity markets, commodity markets and real estate markets. It is the risk of loss, or adverse change, resulting directly or indirectly from fluctuations in the prices of assets. Market Risk at ARE includes the following specific components:

- Currency Risk;
- Interest Rate Risk;
- Spread Risk;
- Equity Risk; and
- Property Risk.

#### Market Risk is also affected by:

- Concentration Risk: The risk that the Company will suffer losses from lack of diversification with regards to a particular sector, industry, geographic region, security, or asset class in the investment portfolio. Concentration Risk also includes the risk of failure to identify and manage correlation risk between insurance/reinsurance operations and invested assets.
- Investment Credit Risk: The risk of loss, or adverse change in financial condition, resulting from fluctuations in the credit standing of issuers of securities and counterparties to which undertakings are exposed, in the form of counterparty default risk, or spread risk, or market risk concentration risk.

The Company's Market Risk SCR is driven by strategic participations in Arch US and UK which are increasing the currency risk (USD and GBP) and concentration risk, while having a material benefit on the assets.

The Company's primary investment objective is to preserve capital and ensure adequate liquidity for policyholder / cedant claims, while supplementing the ROE generated by the reinsurance underwriting operations. The key market risks identified by management are:

- Failure or impairment of investment counterparty; and
- Exposure to foreign currency fluctuations.

#### C.2.2 Material Risk Concentrations

ARE has a diversified portfolio of assets with no material risk concentrations in non-government securities. The Company's investment guidelines have specific single issuer limits, including sovereign and supranational single issuer limits, to prevent asset risk concentrations.

#### **C.2.3** Market Risk Mitigations

ARE mitigates investment risk through the implementation of appropriate controls. These include:

- Regular Board and Senior Management oversight;
- Formal agreements which delegate investment authority to AIM;
- Investment Guidelines which are structured to ensure sufficient liquidity and prevent overexposure to any one risk sector;
- Analysis of quarterly Investment Guideline compliance confirmations issued by Investment Managers, as summarized by ACSI personnel and reviewed by ARE;
- Quarterly review of investment portfolios with ARE Senior Management;
- Appropriate trade due diligence and guideline compliance;
- Utilisation of company approved brokers, investment managers and 3rd party service providers;

- Quarterly testing of Investment Guideline compliance and subsequent review with ARE Senior Management;
- Investment portfolio reporting from AIM to ARE Executive Management and the Board. This reporting includes performance and risk summaries, and includes duration analysis;
- Accounting reconciliations across holdings and risk data; and
- Linkage between ALM ("asset liability matching") and the limits for asset classes, as approved by the Board and set out in this Investment Risk Policy.

## C.2.4 Stress and Sensitivity Testing

A number of ORSA stress tests were performed to reflect the Company's exposure to Market Risk. One economic crisis scenario was performed reflecting an economic crisis centred in Europe.

In this Europe-centric scenario, we consider the impact of such a scenario on C&S claims and exchange rate movements, along with the impact of interest rate movements on bond prices and technical provisions.

Due to the Company's capital strength, while the modelled stresses would result in some deterioration in the Company's capital position, none of the scenarios were considered likely to result in a breach of the SCR. The Company's market risk profile is therefore considered to be resilient to most shocks.

#### **C.2.5** Prudent Person Principle

ARE seeks to manage investment assets subject to the Prudent Person Principle which states that the Board must discharge its duties with the care, skill, prudence and diligence that a prudent person acting in a similar capacity would use in the conduct of an enterprise of similar character and objectives.

The Board of ARE has outlined the following risk management objectives in order to minimise its exposure to Investment Risk in line with the overall ARE Risk Appetite:

- ARE shall adopt a conservative approach to investments and seek to safeguard the assets of shareholders;
- ARE shall hold sufficient investment values and investment liquidity to ensure all liabilities are met as they fall due; and
- ARE shall ensure that there are appropriate policies, strategies and procedures in place to meet these objectives.

ARE adopts a conservative approach to investments and, as articulated in the Company risk management philosophy, limits Investment Risk such that the overall portfolio will consist of high quality fixed income securities and bank deposits, and limits the proportion of total investments that may be represented by other investments. New investment products initiatives fall into the category of other investments and include investments such as equities and all alternative investments. Participation in new investment products are subject to Board approval. In circumstances where new products are being considered by the Company, the following steps will be undertaken:

- Detailed information will be provided describing the nature of the investment such that the Board has full information to properly evaluate the risk;
- The finance function will document the impact of the new product, including an assessment of whether it complies with the prudent person principle;

- A presentation will be made to the Board to explain the rationale for the proposed investment;
   and
- The Risk Committee will separately review the material and consider the impact on ARE's risk appetite and risk profile.

If the proposed investment is approved, ARE's finance and compliance functions will liaise with AIM to revise or develop bespoke Investment Guidelines for the new product where appropriate. In certain circumstances, such as in the case of an investment in a fund, this may not be required.

#### C.3 Credit risk

# C.3.1 Key Credit Risks

ARE has a low appetite for investment credit risk, which is recommended by ARE management and approved by the Board.

ARE is exposed to credit risk from the following sources:

- Investments in fixed income securities;
- Deposits with banking counterparties;
- Reinsurance counterparties; and
- Premiums collectable from cedants.

The key risk is that one or more of these counterparties fail.

The exposure to counterparty default risk includes banks where the Company has short term deposits, insured and insurance intermediary receivable balances and reinsurance agreements including the 85% quota share reinsurance agreement with ARL.

#### C.3.2 Material Risk Concentrations

As at December 31, 2022, the reinsurance recoverable from the quota share reinsurance agreement with ARL is significant however this is partially mitigated by assets in trust to partially collateralise the net recoverable.

#### **C.3.3** Credit Risk Mitigations

ARE mitigates credit risk through the implementation of appropriate controls, processes and procedures.

At purchase, securities must be rated investment grade by at least two of the following ratings agencies (if rated by all three): Moody's, Standard & Poor's or Fitch. If only two of the three agencies rate the security, the lower rating is used to determine eligibility. If only one of the three agencies rates a security, the rating must be "Aa3"/"AA-" or higher.

For the placement of time deposits, banks must be rated at least "A+" or equivalent by Standard & Poor's or Fitch and P-I or equivalent by Moody's at the time of purchase.

Reinsurance and premium receivables are closely monitored and controlled, with short credit periods mitigating any risk exposure. Furthermore, other than the inter-group Quota Share reinsurance, other reinsurance arrangements are split across a number of counterparties, thereby reducing single name exposure.

In addition, ARE requires many counterparties, including ARL, to post significant collateral against reinsurance balances, further mitigating this risk. The collateral posted by ARL is held in a trust account for the benefit of the Company and invested in accordance with investment guidelines agreed with the Company. These guidelines restrict the assets invested into highly rated fixed income government and corporate bonds and limited single name concentrations. Collateral is required to be maintained at a minimum percentage of the net amount recoverables by the Company from ARL. In the event that ARL's rating were to be downgraded this minimum percentage would be subject to graduated increase with the increased percentage being a function of the rating following any such downgrade.

## C.3.4 Stress and Sensitivity Testing

Due to the high level of reinsurance ceded, ARE is exposed to a material amount of counterparty default (credit risk). As one of the Company's most material risks, a downgrade of the Company's immediate parent, ARL, was considered as a scenario. In this scenario it is assumed ARL's rating is downgraded to "B++" from "A+" and that ARL does not post additional capital following its downgrade. Under this stress scenario, which has ARL's downgrade as the sole stress factor, the Company is able to withstand the shock of the downgrade whilst maintaining its SCR ratio above the risk appetite requirement of 120% SCR coverage ratio.

In addition, this ARL downgrade scenario has been selected as part of a Reverse Stress Test carried out in the ORSA, in conjunction with several other adverse scenarios occurring simultaneously. The aim of a reverse stress test is to devise an extreme scenario which would result in the Company's available capital falling below the SCR requirement.

# C.4 Liquidity risk

Liquidity risk is the risk of the Company's inability to realise investments and other assets in order to settle its financial obligations when they fall due. Liquidity risk has low materiality for the Company. One of the objectives of the investment risk policy of the Company is that the Company shall hold sufficient investment values and investment liquidity to ensure all liabilities are met as they fall due. To achieve this objective, the investment risk appetite permits only highly rated securities to be purchased. Risk limits and tolerances have been also set in respect of (i) asset-liability duration matching and (ii) availability of liquid assets. These risk appetites, risk limits and tolerances are monitored by the risk function and reported to the Board and Risk Committee. The Company considers that the composition of its assets in terms of their nature, duration and liquidity are appropriate in order to meet its obligations as they fall due.

In the latest ORSA the Company assessed the Liquidity profile under Stress Scenarios. The stress scenario with the highest peak on a quarterly basis in additional liquidity requirements over the base scenario is the adverse loss experience scenario. Under this scenario, we anticipate that additional liquidity requirements would peak on a quarterly basis at €18.3m in 2023 over the base scenario due to the aggregation of gross of reinsurance claims falling due for payment in the same quarter. We believe that the Company will maintain adequate liquid assets to meet liquidity requirements under the stress scenarios during the projection horizon.

#### C.4.1 Risk Exposure and Material Risk Concentrations

The Company considers its exposure to this risk as low. The Company monitors its liquidity in compliance with its investment risk policy and stated limits and tolerances in respect of the percentage of assets which are invested in liquid investments.

#### C.4.2 Risk Mitigation

Liquidity risk is mitigated by the cash held in investments and bank accounts. There are no planned changes to risk mitigation over the business planning horizon.

## C.4.3 Expected Profit in Future Premium

As of December 31, 2022, the expected profit in future premium is €52.0m.

#### C.5 Operational risk

## C.5.1 Key Operational Risks

Operational Risk means the risk of loss arising from inadequate or failed internal processes, or from personnel and systems, or from external events.

It also includes the risk of loss resulting from failure to comply with laws as well as prudent ethical standards and contractual obligations, and the exposure to litigation from all aspects of business activities.

Within Operational Risk, ARE also includes:

- Group Risk: Risks related to unregulated entities within the Group, implicit or explicit exposure to losses throughout the group ("contagion risk"), risks related to inter-company transactions and double gearing, the extent to which practical, legal, or regulatory barriers to the transfer of capital between group members exist, and other additional risks which individual members of a group face by virtue of their group membership;
- Strategic Risk: Risk that strategic business decisions prove to be ill-founded or poorly executed. Examples of such risk include mergers and acquisitions, moving into new markets, business lines, or regions, changes to the operating model, or failing to anticipate or react to a more general shift in the economic environment, demographics, etc; and
- Reputational Risk: The potential adverse impact of an economic loss through deterioration of reputation, credibility or standing with coinsurance and MGA partners, other customers, brokers and the investor community.

ARE's management has identified the following key operational risks:

- Financial and/or non-financial (e.g. reputational) loss arising from over reliance on outsourced service providers;
- Legal, litigation, regulatory, political and reputational risk;
- Reliance on key individuals (including directors and staff at outsourced service providers);
- Reliance on key brokers;
- Inappropriate overall business strategy or inadequate monitoring of strategic decisions; and
- Risks external to ARE but internal to ACGL.

Those risks classified under the Operational Risk profile have been identified, assessed and articulated in the ARE Risk Register. Relevant risk and control owners report to the CRO, who in turn reports to the Risk Committee, and are responsible for identifying new, emergent or changing risks and any consequent control changes required to realign the risks with the risk appetite.

With respect to Legal Risk, ARE's HOC has the responsibility for monitoring new and pending legislation from the CBI or Irish Government, the European Insurance and Occupational Pensions Authority ("EIOPA") and relevant bodies in other applicable jurisdictions for items that could potentially impact the Company.

In addition, applicable international risks are identified through discussions, meetings and memos with/from law and accounting firms within the jurisdiction of all ACGL entities.

#### C.5.2 Material Risk Concentrations

There is no material Operational Risk concentration outside of our exposure to ACGL.

# C.5.3 Operational Risk Mitigations

ARE has put in place a strong internal control framework which mitigates operational risk. In particular, the following are key controls in managing this risk:

- Appropriate segregation of duties across all functions;
- Systems access controls;
- Four-eyes oversight of all key areas;
- Regular management accounting process including reconciliations and checks;
- Business Continuity and Disaster Recovery Plans;
- All outsourced arrangements conducted under formal agreements and in accordance with the Outsourcing Policy;
- Ongoing oversight and regular audits of outsourced service providers;
- All material contracts reviewed by the ARL General Counsel on behalf of ARE;
- Appropriate reporting to ACGL on all relevant matters to enable oversight;
- Business plans and budgets reviewed quarterly; and
- Appropriate governance structures, including quarterly Board meetings.

#### C.5.4 Stress and Sensitivity Testing

Operational risk is included in the Standard Formula.

As part of its ORSA process, ARE considers those areas of operational risk which may not be adequately covered, such as implementation and compliance with Solvency II and other relevant regulation, investment in subsidiaries and other group risks. In addition, operational risk is stress tested through some of the scenarios:

- large scale operational risk event such as Cyber attack;
- the risk of a credit down-grade of Arch Group (and its impact on the inter-company Quota Share);
   and
- the risk of inappropriate business strategy resulting in loss ratio deviation.

Operational risk comprises a moderate part of ARE's risk profile and the stress tests prove the company's capital buffer to be sufficiently resilient to withstand this risk.

## C.6 Other material risks

A number of other risks are considered to be relevant for the Company, namely group risk, strategic risk, regulatory risk and compliance risk. These risks have not been quantified but are included within the Own Risk and Solvency Assessment.

## Risk Exposure and Material Risk Concentrations

The Company considers the most material exposures in this category of risk are (i) the potential for inappropriate business strategy and (ii) the potential for regulatory breaches.

#### Risk Mitigation

Risk controls, risk monitoring and reporting are considered to be the main method of risk mitigation. There are no planned changes to risk mitigation over the business planning horizon.

## **C.7** Any other information

The onset of global pandemic that emanated in March 2020 resulted in the Company's offices in Dublin, Zurich and London being closed or partially closed during the first quarter of 2022. Government restrictions were eased in most jurisdictions thereafter and a flexible return to work was implemented across all locations. This transition has not led to any diminution of productivity or disruption to the business's operations or performance. The Risk function has undertaken additional risk awareness initiatives and reviews in areas where heightened risks arise from remote working including fraud prevention and 'home' workplace risk assessments.

Following the Russian invasion of Ukraine, the Company is actively monitoring holdings and valuation of its investments, incurred losses, and premium volume, all of which are potentially impacted by the increased volatility and uncertainty. The Risk function's actively involved in this ongoing monitoring.

#### D.1 Assets

The table below sets out the value of the assets of the Company as at 31 December 2022 under Solvency II and Irish GAAP, along with equivalent values as at 31 December 2021.

Assets	2022 Solvency II	2022 Irish GAAP	2021 Solvency II	2021 Irish GAAP
	€′000	€′000	€′000	€′000
Reinsurer's Share of Technical Provisions	816,850	1,460,817	848,637	1,173,138
Deferred Tax Asset	2,932	7,610	2,535	2,734
Investments (including accrued interest & cash)	708,510	708,587	711,485	711,484
Holdings in related undertakings	715,484	628,693	613,752	565,948
Reinsurance Receivables & Insurance and intermediaries receivable	75,601	336,045	35,491	206,302
Deposits to Cedants	32,544	32,549	19,710	19,710
Other assets and non-insurance receivables	31,288	32,073	34,569	34,752
Deferred Acquisition Costs	-	109,595	-	58,397

The following are the bases, methods and main assumptions used for valuation of each material class of assets for Solvency II purpose.

## D.1.1 Deferred tax assets

Deferred tax assets are the temporary differences arising between the tax bases of assets and liabilities and their carrying amounts under Solvency II. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantively enacted by the balance sheet date and that are expected to apply when the related deferred tax asset is realised or the deferred tax liability is settled.

Deferred income tax assets are recognised only to the extent that it is probable that future taxable profit will be available against which the temporary differences can be utilised. Deferred income tax assets and liabilities are offset if there is a legally enforceable right to set off current tax assets against current tax liabilities and if they relate to income taxes levied by the same taxation authority on the same taxable entity.

#### **D.1.2** Holdings in related undertakings

As at December 2022, the Company has two holdings in related undertakings; a 10% holding in Arch Capital Group (U.S.) Inc. ("ACGI"), valued at €549.7m, and a wholly owned subsidiary, Arch Insurance (UK) Limited ("AIUK"), valued at €165.7m.

These valuations are based, in the case of AIUK, on their solvency II excess of assets over liabilities whilst for ACGI the valuation is based on their economic balance sheet prepared on a Solvency II equivalent basis for Bermuda Monetary Authority ("BMA") statutory reporting purposes. The BMA regime has been accepted as Solvency II equivalent by EIOPA.

#### **D.1.3** Investments (other than holdings in related undertakings)

Investments have been valued in accordance with Irish GAAP's fair value model. The Company's investments are managed by Arch Investment Management Limited. The Company receives quarterly report detailing the underlying securities held in the fund. The quarterly reports are reviewed to ensure average financial strength ratings and durations have not moved significantly since the previous quarter. Any unusual movements or discrepancies are discussed with the fund managers. This information is presented to the Group Investment Committee every quarter.

The investments are valued at fair value under Irish GAAP and Solvency II based on market prices at the reporting date, which are quoted prices in active markets for identical assets. Where there are no quoted prices available, the fair value is determined using inputs that are observable for the assets.

There is an amount of €21.4m for an unlisted equity that has been valued using the alternative valuation method in accordance with Solvency II. The Directors have used the equity valuation method, being the closest to the fair value of this equity.

The valuation of investments is consistent with the accounting valuation under Irish GAAP.

#### **D.1.4** Deposits to Cedants

These balances are valued at fair value reflecting the amount held at 31 December 2022, translated at the closing exchange rate for balances not denominated in the reporting currency. No estimates or judgements are required in the valuation.

There has been no change in the recognition and valuation basis during the period and there are no differences between the valuation for Solvency II and the GAAP valuation.

#### **D.1.5** Insurance and intermediaries receivables

Insurance and intermediaries receivables balance represents premiums owed by cedants. Outstanding premiums are valued at fair value and due to the short-term nature of the receivable no adjustments to valuation are required. The valuation of insurance and intermediaries receivables is consistent with the accounting valuation under Irish GAAP except that the share of insurance and intermediaries balances which are not yet due at the valuation date are deducted from the balance and included in the technical provisions cashflow.

#### D.1.6 Cash and cash equivalents

The Company's cash holdings are held in major currencies, which are EUR, GBP and USD, and also in ZAR, comprising a mix of bank deposits and cash funds. The non-EUR balances are translated into EUR at the balance sheet closing rate.

Cash and cash equivalents are valued at fair value by the relevant financial institution, and the Company receives monthly statements at the period end to confirm the balances held. There are no significant estimates or judgements used in valuing cash holdings due to the nature of the asset.

There has been no change in the recognition and valuation basis during the period and the valuation of cash and cash equivalents under Solvency II is consistent with the accounting valuation under Irish GAAP.

#### **D.1.7** Other assets and non-insurance receivables

Other assets and non-insurance receivables have been valued using the alternative valuation method in accordance with Solvency II. The Directors have used the cost approach or current replacement cost approach, being the closest to the fair value of these assets.

The valuation of other assets and non-insurance receivables is consistent with the accounting valuation under Irish GAAP, apart from goodwill, which is recognised on an Irish GAAP basis, but not on a Solvency II basis.

## D.1.8 Deferred acquisition costs / Goodwill

The following are the material differences in valuation of assets between Solvency II and financial statements prepared in accordance with Irish GAAP that are not already explained in the previous sections.

In the financial statements, acquisition costs which represent commission and other related expenses are deferred over the year in which the related premiums are earned. To the extent that acquisition costs are deferred and considered irrecoverable against the related unearned premiums, they are written off to net operating expenses as incurred.

Solvency II balance sheet is prepared based on the best estimate of future cash flow basis. Therefore, deferred acquisition costs are being excluded from the Solvency II balance sheet.

Goodwill recognised under Irish GAAP is similarly excluded from the Solvency II balance sheet.

# D.2 <u>Technical provisions</u>

# **D.2.1** Results summary

The following table sets out the Solvency II technical provisions by grouping as at 31 December 2022.

31 December 2022	Claims	Premium	Risk Margin	Solvency II
Net of Retrocession and inter-company	Provisions	Provisions	(€'000)	<b>Technical Provisions</b>
Quota Share	(€'000)	(€'000)	(€ 000)	(€'000)
Accident & Health Reinsurance	3,699	(2,175)	1,625	3,149
Property Reinsurance	17,362	(8,415)	8,650	17,596
Liability Reinsurance	7,015	7,817	3,439	18,271
Credit & Surety Reinsurance	13,850	5,661	11,488	30,999
Non-Proportional Reinsurance	74,516	(34,989)	33,746	73,274
Grand Total	116,442	(32,101)	58,948	143,289

For comparison purposes, the following table sets out the Solvency II technical provisions by grouping as at 31 December 2021.

31 December 2021 Net of Retrocession and inter-company Quota Share	Claims Provisions (€'000)	Premium Provisions (€'000)	Risk Margin (€'000)	Solvency II Technical Provisions (€'000)
Accident & Health Reinsurance	2,784	(575)	458	2,667
Property Reinsurance	11,587	(1,651)	6,847	16,783
Liability Reinsurance	8,111	(2,994)	2,848	7,965
Credit & Surety Reinsurance	15,461	6,754	9,847	32,062
Non-Proportional Reinsurance	97,917	(31,531)	49,856	116,242
Grand Total	135,860	(29,997)	69,856	175,719

The groupings above are made up of the following Solvency II Lines of Business ("LoB").

Line of Business grouping	Solvency II line of business			
Accident & Health Reinsurance	Medical expense			
	Workers' compensation			
Liability Reinsurance	Motor vehicle liability			
	General liability			
Property Reinsurance	Other motor			
	Marine, aviation and transport			
	Fire and other damage to property			
Credit & Surety Reinsurance	Credit and suretyship			
Non-Proportional Reinsurance	Non-proportional health reinsurance			
	Non-proportional casualty reinsurance			
	Non-proportional marine, aviation and transport reinsurance			
	Non-proportional property reinsurance			

The increase of in the overall technical provisions is a reflection of the growth in the business over the past 12 months.

## **D.2.2** Calculation Methodology

Under Solvency II an economic balance sheet is required – which requires a market valuation of technical provisions. The overarching principle for valuing technical provisions under Solvency II is the current amount undertakings would have to pay if they were to transfer their (re)insurance obligations immediately to another undertaking.

The starting point for valuing the Company's Technical Provisions ("TPs") is the Company's Irish GAAP basis reserves for loss and allocated loss adjustment expenses ("Loss Reserves"). Cash flows associated with those Loss Reserves, along with unearned premium reserves and provisions for other components of economic basis TPs, are calculated for each homogenous risk group using the approach outlined below.

## (a) Best Estimate Liability

The best estimate liability ("BEL") is calculated from the cashflows in respect of the claims provisions and premium provisions. The best estimate liability represents the present value of future cashflows. The present value is calculated based on the timing of cashflows and on yield curves provided by EIOPA. The best estimate liability is determined on a gross, ceded and net basis for both the claims provisions and the premium provisions.

## (b) Premium Receivable

Premium receivable in respect of the portion of the GAAP premium receivable not yet due on the valuation date is included in the premium provisions cashflows. A consistent approach is applied to calculation of ceded premium payable.

#### (c) Premium in respect of Bound But Not Yet Incepted Business

The Company's technical provision calculation allow for business that is bound but not yet incepted ("BBNI") at the valuation date.

The premium provisions include the future premium cashflows in respect of the BBNI business up to the relevant contract boundary.

# (d) Future loss and allocated loss adjustment expense

Future loss and allocated loss adjustment expense cashflows are projected in respect of the GAAP Loss Reserves in order to calculate claims provisions. The Company does not consider that there are any implicit or explicit margins in the GAAP Loss Reserves.

Future loss and allocated loss adjustment expense cashflows are projected in respect of the GAAP unearned premium reserves and BBNI premium in order to calculate premium provisions. The projection uses business planning assumptions in respect of future loss ratios on unearned premium reserves and not yet incepted business.

# (e) ENIDs

The Solvency II technical provisions must allow for events not in data ("ENIDs"). This identifies that the Company has potential exposure to an extreme loss arising from severe liability catastrophe. An ENID loading has been derived by the Company using a truncated distribution approach and is applied to future claim cashflows in both the claims provisions and premium provisions.

#### (f) Expenses

Acquisition costs directly attributable to the future premium receivable are determined based on the terms of the contracts which generate the premium receivable.

In addition, an allowance for unallocated loss adjustment expenses, administrative expenses and investment management expenses associated with the settlement of the best estimate liabilities is included in the technical provisions.

# (g) Adjustment for counterparty default

An adjustment for counterparty default is applied to the ceded technical provisions. The adjustment for counterparty default uses the Probability of Default ("PD") consistent with the Credit Quality Steps specified in EIOPA guidance in respect of the AM Best financial strength rating for reinsurance counterparties.

## (h) Risk Margin

The Risk Margin is calculated based on the Level 3 of Simplifications in the EIOPA guidance which projects future SCR values based on the assumption that the SCR to Net BEL ratio is constant through time. A ratio of SCR to Net BEL is determined as of the valuation date. This ratio is applied to future BEL estimates at each 1-year interval until liabilities are fully runoff to estimate future SCR requirements. A 6% cost of capital is applied to all SCR estimates though time to estimate the cost of capital to support the liabilities. The resulting series of costs of capital requirements are present valued to the valuation date using the yield curve for the reporting currency of the company with a 1-year lag per the EIOPA guidance material.

#### D.2.3 Material Changes since Last Reporting Period

There has been no material change in the calculation methodology for technical provisions since the last reporting period. Some minor changes were made to the process and assumptions used for technical provisions. The source system for the data used to define the business that was Bound But Not Incepted (BBNI) was revised to ensure this data was available earlier in the process. In addition, the Natural Catastrophe exposure has been refined at treaty level.

## **D.2.4** Impact of Reinsurance

There has been no material change in the calculation methodology for technical provisions since the last reporting period. Some minor changes were made to the process and assumptions used for technical provisions. The source system for the data used to define the business that was Bound But Not Incepted (BBNI) was revised to ensure this data was available earlier in the process. In addition, the Natural Catastrophe exposure has been refined at treaty level.

The held provisions for Solvency II correspond to the probability-weighted average of all future cash flows including cash flows recoverable from reinsurance contracts and special purpose vehicles. This takes account of the time value of money, using the relevant risk-free interest rate, and the adjustment for the expected losses due to the default of the counterparty (i.e. bad debt).

Recoverables from reinsurance contracts are shown separately on the asset side of the balance sheet (as "recoverables from reinsurance contracts"). Recoveries due on settled claims do not sit within the technical provisions, i.e. those where collection notes have been sent out but not received – reinsurance receivables.

Calculation of amounts recoverable from reinsurance contracts are performed under the same principles as for calculation of the gross best estimate. Risk margins are not required in respect of reinsurance and special purpose vehicle recoverables, as risk margins are calculated at a net level.

Gross and net best estimate reserves are estimated separately for each underwriting year. Reinsurance cash flows are then derived as the difference between gross and net cash flows.

Reserves are calculated on both gross and net (post internal quota share) bases. The net figures are produced in two stages:

- Firstly, applying all external reinsurance; and
- Secondly applying the intercompany quota share (85% placement).

Cash inflows stemming from ceded reinsurance income are calculated as a factor of net premiums.

In addition, the principle of correspondence underlying the calculation of reinsurance recoveries is also considered, as set out in the next section.

## **D.2.5** Level of Uncertainty

Uncertainty in technical provisions arises from a number of sources:

- The estimates for outstanding losses are based on known information at the balance sheet date.
   Ultimate settlement of these claims may differ from these estimates;
- The estimates for future losses on both expired and unexpired business are based on actuarial assumptions reflecting past performance and anticipated future changes. These assumptions may ultimately prove to differ from actual experience;
- The estimates for expenses are based on reasonable judgement reflecting past experience and on assumptions as to the run-off period. Either of these factors may differ from ultimate experience;
   and
- Events not in data are, by their nature unpredictable and any allowance made could prove to be over-prudent or insufficient.

The Company follows a robust process in setting appropriate assumptions underlying the calculation of technical provisions. Actual performance is monitored against expectations on an ongoing basis to ensure assumptions are updated as required.

Stress testing was performed on the Solvency II Technical Provisions as at 31<sup>st</sup> December 2022 in order to give an indication of sensitivity around loss ratio assumptions.

The following table shows net Best Estimate of Liabilities (i.e. the claims provision and premium provision, but not including the Risk Margin) in stressed scenarios (losses 5% and 10% higher than expected).

	Base Case (€'000)	Losses +5% (€'000)	Losses +10% (€'000)
Net Best Estimate Liabilities	84,340	92,306	100,272
Impact		7,966	15,931

The above results of sensitivity testing should be considered in the context of the Company's solvency profile. As at December 31<sup>st</sup>, 2022, the Company's SCR was €463.5m, against which it held eligible own funds of €843.0m, equating to SCR coverage of 181.9%. Without considering the impact on SCR, the more

extreme of the scenarios above (losses 10% higher than expected), would reduce the SCR coverage ratio to 178.5%.

## D.2.6 Material Differences between Irish GAAP and Solvency II

Whilst some of the approaches and techniques applied under Solvency II are similar to those followed under the existing Irish GAAP rules, there are other rules where there will be significant changes. These include:

- Movement to a cash flow basis for valuation of both gross business and reinsurance;
- Removal of any implicit or explicit margins within technical provisions to give a "true best estimate" for solvency purposes, defined as the mean of the full range of possible future outcomes;
- Introduction of the valuation of very low probability extreme events including latent claims, referred to as an allowance for "events not in data" or ENIDs;
- Removal of the requirements to hold an unearned premium reserve and to allow for other non-monetary items. These are replaced by "premium provisions", valued on a best estimate basis.
   This also includes a requirement to take account of all future premium cash inflows;
- Movement to recognising contracts on a "legal obligation basis". This will mean the inclusion
  of business currently not valued as part of technical provisions for example 1 January renewals
  entered into prior to a 31 December valuation;
- Introduction of discounting of cash flows, leading to increased volatility in reserves;
- Introduction of the principle of a market consistent basis and calculation of a "risk margin"; and
- Valuation of liabilities segmented by at least Solvency II lines of business.

#### **D.2.7** Other Comments

The Company does not apply the matching adjustment referred to in Article 77 b of Directive 2009/138/EC, the volatility adjustment referred to in Article 77 d of Directive 2009/138/EC, the transitional adjustment to the risk-free interest rate term structure referred to in Article 308 c of Directive 2009/138/EC, or the transitional deduction referred to in Article 308 d of Directive 2009/138/EC.

Due to the nature of the business and the low level of materiality in respect of policyholders opting to lapse, no lapse assumption has been applied to future premium in the calculation of technical provisions.

Future management actions are not considered relevant for this business.

# D.2.8 Irish GAAP to Solvency II Comparison

The table below sets out the movement analysis between Irish GAAP and Solvency II for the Company as at 31 December 2022.

2022 Technical Provisions	Gross	Ceded	Net
GAAP to Solvency II	€'000	€'000	€'000
Claims Provisions	1,081,128	964,686	116,442
Premium Provisions	(179,937)	(147,836)	(32,101)
Risk Margin	58,948	-	58,948
Solvency II Technical Provisions	960,139	816,850	143,289
GAAP Reserves (including ULAE)	1,224,874	1,115,043	109,831
Remove margins	-	-	-
Allowance for ENID	15,461	13,600	1,861
Change of Expense Basis	23,386	-	23,386
Adjustment for Counterparty Default	-	(369)	369
Reinsurance Receivables/Payables	-	-	-
Discounting impact	(182,593)	(163,589)	(19,004)
Currency Revaluation	-	-	-
Remove booked ULAE	-	-	-
Solvency II Claims Provisions	1,081,128	964,686	116,442
GAAP Reserves (Unearned Premium)	372,993	345,773	27,219
Remove Unearned Premium Reserve	(372,993)	(345,773)	(27,219)
Future Premium (net of Acquisition Costs)	(406,540)	(349,807)	(56,734)
Future Losses and ALAE	525,480	471,469	54,011
Remove margins	-	-	-
Allowance for ENID	7,449	6,678	771
Change of Expense Basis	10,510	-	10,510
Adjustment for Counterparty Default	-	(498)	498
Premium Receivables	(260,266)	(225,907)	(34,359)
Reinsurance Receivables/Payables	-	-	-
Discounting impact	(56,569)	(49,772)	(6,797)
Solvency II Premium Provision	(179,937)	(147,836)	(32,101)

The movement from Irish GAAP basis reserves and Solvency II Technical Provisions applies in the same manner for each Line of Business.

For comparison purpose, the table below sets out the GAAP to Solvency II movement as at 31 December 2021.

2021 Technical Provisions	Gross	Ceded	Net
GAAP to Solvency II	€'000	€'000	€'000
Claims Provisions	1,057,410	921,553	135,860
Premium Provisions	(102,913)	(72,915)	(29,997)
Risk Margin	69,856	-	69,856
Solvency II Technical Provisions	1,024,353	848,637	175,719
GAAP Reserves (including ULAE)	1,069,158	950,879	118,279
Remove margins	-	-	-
Allowance for ENID	13,808	12,085	1,723
Change of Expense Basis	21,310	-	21,310
Adjustment for Counterparty Default	-	(423)	423
Reinsurance Receivables/Payables	-	-	-
Discounting impact	(46,866)	(40,988)	(5,875)
Currency Revaluation	-	-	-
Remove booked ULAE	-	-	-
Solvency II Claims Provisions	1,057,410	921,553	135,860
GAAP Reserves (Unearned Premium)	248,749	222,258	26,490
Remove Unearned Premium Reserve	(248,749)	(222,258)	(26,490)
Future Premium (net of Acquisition Costs)	(343,322)	(286,815)	(56,507)
Future Losses and ALAE	414,566	374,705	39,861
Remove margins	-	-	-
Allowance for ENID	5,867	5,289	578
Change of Expense Basis	8,291	-	8,291
Adjustment for Counterparty Default	-	(173)	173
Premium Receivables	(171,005)	(150,496)	(20,509)
Reinsurance Receivables/Payables	-	-	-
Discounting impact	(17,310)	(15,425)	(1,885)
Solvency II Premium Provision	(102,913)	(72,915)	(29,997)

#### **D.3** Other liabilities

The table below sets out liabilities other than technical provisions on the Solvency II balance sheet as at year-end 2022 and 2021:

Other Liabilities	2022 Solvency II €'000	2022 Irish GAAP €'000	2021 Solvency II €'000	2021 Irish GAAP €'000
Deposits from Reinsurers	-	-	-	-
Insurance & intermediaries payables	58,738	57,255	13,248	13,247
Reinsurance payables	517,928	740,564	420,400	570,895
Payables (trade, not insurance)	3,056	3,850	1,914	1,595
Ceded deferred excess commission	-	10,380	-	14,803
Ceded deferred acquisition costs	-	94,691	-	48,834
Payables (securities)	-	77	-	15,528
Any Other Liabilities, not elsewhere shown	339	1,027	15,529	318
Total Other Liabilities	580,061	907,845	451,091	665,221

The following are the bases, methods and main assumptions used for valuation of each material class of other liabilities for Solvency II purpose.

#### D.3.1 Reinsurance payables

Reinsurance payables balance represents amounts payable to reinsurers in respect of ceded premiums. Reinsurance payables are valued at fair value. The valuation of reinsurance payables is consistent with the accounting valuation under Irish GAAP except that the share of reinsurance balances which are not yet due at the valuation date are deducted from the balance and included in the technical provisions cashflow.

#### **D.3.2** Payables (trade, not insurance)

The valuation of payables (trade, not insurance) is consistent with the accounting valuation under Irish GAAP.

#### **D.3.3** Ceded deferred Excess commissions

In the financial statements, ceded deferred excess commissions represent ceding commission received in excess of original acquisition expenses on assumed business, and are deferred over the year in which the related reinsurers' share of premiums are earned.

Solvency II balance sheet is prepared based on the best estimate of future cash flow basis. Therefore, ceded deferred ceded deferred excess commissions are being excluded from the Solvency II balance sheet.

#### D.3.4 Ceded deferred acquisition costs

In the financial statements, ceded acquisition costs which represent commission and other related expenses, are deferred over the year in which the related reinsurers' share of premiums are earned. To the extent that ceded deferred acquisition costs are deferred and considered irrecoverable against the related reinsurers' share of unearned premiums, they are written off to net operating expenses as incurred.

Solvency II balance sheet is prepared based on the best estimate of future cash flow basis. Therefore, deferred ceded acquisition costs are being excluded from the Solvency II balance sheet.

#### **D.3.5** Insurance and Intermediaries Payables

The valuation of Insurance and Intermediaries payables is consistent with the accounting valuation under Irish GAAP.

# D.4 Alternative methods for valuation

As previously stated, (i) unlisted equities in the investment portfolio and (ii) other assets and non-insurance receivables have been valued using the alternative valuation method in accordance with Solvency II.

## D.5 Any other information

The Company has a number of risk management policies in place that aim to protect the balance sheet against various risks. These include the investment risk policy and underwriting and reserving risk policy. Further information on the Company's risk management is provided in Section B above.

No other material information to report as of 31 December 2022.

## E.1 Own Funds

# **E.1.1** Management of Own Funds

The Company has adopted a capital management policy setting out the methodology and procedures to provide oversight of the Company's own funds. The strategic objectives articulated in the capital management policy are (i) to ensure compliance with the Company's regulatory capital requirements, (ii) to manage and allocate capital efficiently to achieve sustainable returns and facilitate growth objectives as articulated in the Company's business plans; and (iii) to ensure access to capital markets on competitive terms, so that the Company's overall cost of capital is minimised. To achieve these objectives, the Company strives to maintain capital levels that are consistent with its risk appetite, corporate strategy and statutory minimum requirements, at both a point in time and on a forward-looking basis. The Company's time horizon for business planning is one year, however the capital planning horizon spans three years.

The Company has adopted a capital management plan which is reviewed annually and sets out the methodology and procedures to provide oversight of the Company's own funds. The capital management plan articulates solvency capital thresholds, corrective actions to be taken if the thresholds are reached and potential sources of capital for the Company and their estimated timeframe of realisation.

High level roles and responsibilities in relation to capital management activities are outlined below.

- Board: Sole responsibility for approving the capital management policy and plan. Overall responsibility for monitoring capital management;
- Risk Committee: Reviews the capital management policy and plan and makes recommendations to the Board. Reviews and monitors the key capital management metrics and tolerances and presents key capital management information to the Board on an ongoing basis;
- Audit Committee: Responsible for aligning the investment strategy with the capital management policy and plan, and ensuring an appropriate level of funds are available to meet the Company's obligations in a timely manner and at a reasonable cost;
- Finance Function: Responsible for producing the reports necessary for appropriate monitoring that
  the capital management policy is being followed and monitoring execution of the capital
  management plan; and
- Risk Management Function. Responsible for maintaining and developing the capital management policy and plan, and for maintaining the SCR and MCR calculations.

In the event that the ongoing monitoring indicates that Company's capital position is outside of risk appetite, corrective actions shall, as deemed appropriate, be taken. Proposed corrective actions shall be initiated by the Finance Function, after receiving approval from the Board on the appropriate corrective action to be taken.

The Company has identified management actions which would provide capital relief if required:

- Restricting line sizes / product redesign / repricing; and
- Discontinue / Run off certain lines of business.

Estimated timeframe for realization of relief from the management actions is six months. Other potential sources of capital which the Company has identified are:

- Additional capital sourced from Group through contributed capital, capital loan or additional reinsurance arrangements; and
- Capital sourced from outside parties, e.g., merger, private equity.

Estimated timeframe for realization of relief from the potential sources of capital from the Group is 1 to 3 month. Estimated timeframe for realization of relief from outside parties is three months to one year.

In addition to the Capital Management Plan, the Company has prepared a Recovery Plan to enable it to identify recovery options to restore financial strength and viability if it comes under severe stress. The goal of recovery planning is twofold: to aid the Company in understanding its own risks from severe stress scenarios, and to be better prepared to provide an effective response in the event of the Company experiencing such scenarios. The focus is on situations that pose a serious risk to the Company's compliance with regulatory solvency requirements and, by extension, the viability of the Company or any material part of its business. The purpose of the Recovery Plan is not to demonstrate that severe financial stress is very unlikely but to articulate what actions could and would be taken if such a crisis ever arose.

## E.1.2 Classification of Own Funds

The Company's own funds consist mostly of Tier 1 own funds, along with a small amount of Tier 3 own funds (deferred tax asset). Tier 1 funds are comprised of paid-in ordinary share capital, share premium account related to ordinary share capital, reconciliation reserve and other own funds (investments in related undertakings).

Composition of Own Funds	Yea	r Ended 3	1/12/20	22	Year	Ended 31,	/12/202	21
Own Funds (€'000)	Total	Tier 1	Tier 2	Tier 3	Total	Tier 1	Tier 2	Tier 3
Paid-in ordinary share capital	50,000	50,000	)		50,000	50,000		
Share premium account related to ordinary	24,341	24,341			24,341	24,341		
share capital								
Reconciliation Reserve:	571,770	571,770	)		519,893	519,893		
Net Deferred Tax Assets	2,932			2,932	2,535			2,535
Other Own Fund items approved by the CBI	193,964	193,964			193,964	193,964		
Total Own Funds	843,007	840,076		2,932	790,733	788,198		2,535

The reconciliation reserve equals the excess of assets over liabilities less other own funds items as at the reporting date and represents retained earnings less adjustments from GAAP to Solvency II valuation.

The difference between the equity shown in the Company's financial statements and the excess of the assets over liabilities as calculated for solvency purposes arises due to differences in valuation of technical provisions and other items outlined in the subsections below.

## E.1.3 Terms and Conditions of Own Funds

There is no restriction on the availability or transferability of the own funds.

## E.1.4 Differences in Own Funds between Financial Statements and Solvency II Valuation

The difference between the equity shown in the Company's Financial Statements and the Excess of the Assets over Liabilities as calculated for solvency purposes arises due to the valuation of technical provisions, the ineligibility of the deferred acquisition costs (and deferred ceded acquisition costs) and goodwill, the adjustment to the deferred tax asset, the valuation of payables and receivables and differences in the valuation of investments in related undertakings.

Differences in Own Funds	Year Ended	Year Ended
(Euro in thousands)	31/12/2022	31/12/2021
Equity shown in Financial Statements	810,259	789,342
Technical Provisions Valuation	(6,239)	(30,947)
Payables & Receivables	(38,605)	(20,510)
Economic Valuation of Investments in Subsidiaries	86,788	47,804
Goodwill	0	0
Deferred Acquisition Costs Eligibility	(4,440)	5,243
Deferred Tax Asset Adjustment	(4,678)	(199)
Deferred Tax Liabilities	0	0
Other	(77)	0
Excess of Assets over Liabilities for solvency purposes	843,007	790,733

## E.2 Solvency Capital Requirement and Minimum Capital Requirement

## E.2.1 Calculation of SCR and MCR

In respect of the calculation of the SCR and MCR:

- The Company uses the Standard Formula;
- Undertaking specific parameters are not used;
- No capital add-ons are applied to the SCR figures;
- The simplifications outlined in Articles 107, 108, 110, 111 and 112 Commission Delegated Regulation
   (EU) 2015/35 apply to the Counterparty default risk sub-module;
- No simplifications have been used in the other risk sub-modules; and
- The MCR is calculated based on the Linear MCR based on the net of reinsurance best estimate technical provisions and the net written premiums in the last 12 months. Then a floor of 25% of the SCR and a cap of 45% of the SCR is applied with an absolute floor of €3.9m also applied to derive the final MCR requirement.

As at 31 December 2022, the SCR is €463.5m. A breakdown of SCR by risk category is set out in the following table.

Risk Category	2022 SCR (€'000)	2021 SCR (€'000)
Market risk	412,781	370,401
Counterparty default risk	45,151	33,869
Life underwriting risk	-	-
Health underwriting risk	13,475	10,131
Non-life underwriting risk	97,786	95,816
Diversification	(101,035)	(89,577)
<b>Basic Solvency Capital Requirement</b>	468,158	420,640
Operational risk	27,036	28,635
Loss-absorbing capacity of deferred taxes	(31,728)	(21,076)
Solvency Capital Requirement	463,466	428,199

The evaluation of the loss absorbing capacity for deferred tax remains aligned with the standard formula review by EIOPA amending Delegated Regulation (EU) 2015/35 supplementing Directive 2009/138/EC. The evaluation of loss absorbing capacity for deferred tax is aligned with the Company strategic plan.

Market risk is driven by company strategic participations in Arch US and UK which are increasing the currency risk (USD and GBP) and concentration risk. This is also driving the increase of the own funds.

As at 31 December 2022, the MCR is €115.9m. The calculation of MCR is set out in the following table:

MCR Calculation		
	Net of Reinsurance	Net written premiums
Line of Business	Best Estimate TPs	last 12 months
Medical expense	1,115	6,443
Income protection	-	-
Workers' compensation	409	292
Motor vehicle liability	1,686	4,667
Other motor	822	4,297
Marine, aviation and transport	451	152
Fire and other damage to property	7,674	18,830
General liability	13,147	1,859
Credit and suretyship	19,511	17,233
Non-proportional health reinsurance	-	4,411
Non-proportional casualty reinsurance	42,812	12,342
Non-proportional marine, aviation and transport reinsurance	31	-
Non-proportional property reinsurance	-	9,591
Linear MCR		22,744
SCR		463,466
Combined MCR		115,866
Absolute Floor of the MCR		3,900
Minimum Capital Requirement		115,866

## E.2.2 SCR ratio and MCR ratio

As at 31 December 2022, the ratio of eligible own funds to SCR and MCR are outlined in the table below.

Solvency Coverage	2022 (€'000)	2021 (€'000)
Total eligible own funds to meet the SCR	843,007	790,733
Total eligible own funds to meet the MCR	840,076	788,198
SCR	463,466	428,199
MCR	115,866	107,050
Ratio of Eligible own funds to SCR	181.9%	185%
Ratio of Eligible own funds to MCR	725.0%	736%

# E.3 Use of the duration-based equity risk sub-module in the calculation of the SCR

The duration-based equity risk sub-module is not used in the calculation of the SCR.

# E.4 Differences between the standard formula and any internal model used


Not applicable.

# E.5 Non-compliance with the MCR and non-compliance with the SCR

The Company complies with the SCR and MCR during 2022.

# **E.6** Any other information

No other material information to report as of 31 December 2022.



#### **AF**

Actuarial Function.

# Allocated Loss Adjustment Expenses (ALAE)

A provision to cover the estimated expenses relating to the handling of outstanding claims (including IBNR claims), which are allocated directly to case estimates. It usually includes external expenses such as legal expenses and claims assessors' fees.

#### ARE

Arch Reinsurance Underwriting Europe dac.

#### **BEL**

Best Estimate Liability.

#### **CBI**

Central Bank of Ireland.

## **Data Integration Layer (DIL)**

An automated ETL process implemented in 2016 that takes data from various sources and formats it correctly for use in the Risk Integrity platform. Developed externally by consultant Genpact with expertise hired at a Group level for on-going maintenance and development.

## Extract, Transform & Load (ETL)

Refers to a process in database usage and especially in data warehousing that performs:

- 1. Data extraction extracts data from homogeneous or heterogeneous data sources
- 2. Data transformation transforms the data for storing it in the proper format or structure for the purposes of querying and analysis

Data loading – loads it into the final target database

#### **EPI**

Estimated Premium Income.

#### **Excess of loss**

A generic term describing reinsurance which, subject to a specified limit, indemnifies the reinsured company against all or a portion of the amount of loss in excess of the reinsured's specified loss retention. The term is generic in deserving various types of excess of loss reinsurance, such as per risk (or per policy), per occurrence (Property Catastrophe or Casualty Clash), and annual aggregate. The loss retention in excess of loss reinsurance should not be confused with the policy retention in surplus share re-insurance, which always refers to a pro rata form of reinsurance in which, once a cession of insurance is made, the reinsured and reinsurer share insurance liability, premium and losses, beginning with the first dollar of loss. Also known as Non-proportional Reinsurance.

#### **GWP**

Gross Written Premium.

#### **HoAF**

Head of Actuarial Function.

#### **Incurred Claims**

The sum of the paid claims and outstanding notified claims (or case estimates or case reserves) at any point in time.

#### **Incurred But Not Reported Reserve (IBNR)**

Amount of reserves required for claims in respect of claim events that have occurred before the accounting date but have not yet been reported to the insurer by that date. Within this report, IBNR includes IBNER.

#### **Initial Expected Loss Ratio (IELR)**

The claim ratio expected on a book of business at inception.

#### **Outstanding**

Unless specifically stated otherwise the term outstanding is used in this report to denote the amount of notified case reserves.

#### **REGIS**

Reinsurance Group Information System – The Company's Underwriting, Accounting and Claims system.

#### RI

Risk Integrity - A Solvency II platform created by Moody's and purchased by the Company in 2016, used for pillar 1 and pillar 3 reporting. Produces QRTs and generates the XBRL required by the CBI.

#### **ROE**

Return on Equity (profit divided by capital).

#### QCR

Quarterly Change Report.

#### **QRTs**

Quantitative Reporting Templates.

#### SII

Solvency II.

#### **Quota-share**

A form of pro rata reinsurance (proportional) in which the reinsurer assumes an agreed percentage of each insurance being reinsured and shares all premiums and losses accordingly with the reinsured. Quota share reinsurance is usually arranged to apply to the insurer's net retained account (i.e., after deducting all other reinsurance except perhaps excess of loss catastrophe reinsurance), but practice varies. A quota share reinsurer may be asked to assume a quota share of a gross account, paying its share of premium for other reinsurance protecting that gross account.

# **Ultimate Loss Ratio (ULR)**

The ratio of the ultimate cost of claims in a period to the corresponding ultimate premiums from that period either gross or net of reinsurance.

## Unallocated Loss Adjustment Expenses (ULAE)

A provision to cover the estimated expenses relating to the handling of outstanding claims (including IBNR claims) which are not allocated directly to case estimates. It usually includes such expenses as salaries of claims department staff.

#### **Underwriting Year / UWY**

Describes written premium and claims data that is grouped according to the year in which the business is written irrespective of when they are actually reported or paid and irrespective of the month in which the claim event occurs.

## **Unearned Premium Reserve (UPR)**

The amount set aside from premiums written before the accounting date to cover risks incurred after that date.

## **Written Premium**

Amount of premium, either gross or net of reinsurance, for which cover commenced in an accounting period.

Attached are the public QRTs required as part of the report. We note in some cases totals do not match the sum of individual fields due to rounding.

There are nominal differences between Paid claims in S.19.01 and paid claims under GAAP due to difference in the recognition of the effect of exchange rates.

# Annex I S.02.01.02

# Balance sheet

Part			
Section   1001			Solvency II value
Deferred as assisted   1909	Assets		
Image  Boses assets	Goodwill	R0010	
Defends at as assets	Deferred acquisition costs	R0020	
Peasion benefit surplivs   Peasion   Peasion benefit surplivs   Peasion   Peasi	Intangible assets	R0030	
Property plant & couptiments theld for own use   R000	Deferred tax assets	R0040	2,932
Investments (other than saces held for index-linked and unit-linked contracts)	Pension benefit surplus	R0050	
Property (other than for own use)   R0000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   17.5,484   18.000   18.00	Property, plant & equipment held for own use	R0060	308
Hollings in related undertakings, including participations		R0070	1,358,881
Equities   Institute   Insti		R0080	
Equities - lained   Equi			715,484
Equities - unlitted   190136   391.654   391.054   391	Equities		
Bonds         R01140         38.971.551           Government Bonds         R01161         36.972.51           Copenate Bonds         R01160         10.122.14           Structured bourseline         R01160         4.444           Collective Investments Undertakings         R01198         5.17.43           Derivatives         R01990	•		
Cooperation Bonds	Equities - unlisted		
Comparison			
Structured notes   R0100	Government Bonds		<del></del>
Collective Investments Undertakings	•		104,234
Collective Investments Undertakings		-	1
Deposits other than eash equivalents			
Deposits other than cash equivalents   R0200   R0210			51,743
Other investments         R0210           Assets held find index-inhed and unit-linked contracts         R0230           Loans and mortgages         R0240           Loans and mortgages to individuals         R0250           Other loans and mortgages         R0260           Reissurance receivables from:         R0270         816,850           Non-life and health similar to non-life         R0280         816,850           Non-life excluding health         R0290         766,702           Health similar to non-life         R0300         50,147           Life and health similar to life, excluding health and index-linked and unit-linked         R0310         50,147           Life index-linked and unit-linked         R0330         50,147           Life index-linked and unit-linked         R0330         32,544           Life index-linked and unit-linked         R0330         32,544           Life index-linked and unit-linked         R0330         32,544           Light excluding health and index-linked and unit-linked         R0330         32,544           Light excluding health and index-linked and unit-linked         R0330         32,544           Light excluding health and index-linked and unit-linked         R0330         5,166           Own shares (held directly)         R0330 <td< td=""><td></td><td></td><td>+</td></td<>			+
Assets held for index-linked and unit-linked contracts   R0220   R0240   R0240   R0240   R0250   R02			
Loans and mortgages         R0230           Loan son policies         R0250           Chean and mortgages to individuals         R0250           Other loans and mortgages         R0260           Reinsurance recoverables from:         R0270         816,850           Non-life and health similar to non-life         R0280         816,850           Non-life and health similar to non-life         R0290         766,702           Heath similar to non-life and health similar to life, excluding health and index-linked and unit-linked         R0310			
Loans on policies			+
Lans and mortgages to individuals   R0250   R0260			+
Other loans and mortgages         R0260         R16,850           Reinsurance recoverables from:         R0270         816,850           Non-life and health similar to non-life         R0290         766,702           Non-life excluding health         R0390         50,147           Life and health similar to non-life         R0390         50,147           Life and health similar to life, excluding health and index-linked and unit-linked         R0310         ————————————————————————————————————	· ·		+
Reinstrance recoverables from:   R0270   R16,850   R0280   R16,850   R0280   R16,850   R0280   R0280   R0280   R0280   R0280   R0280   R0280   R0280   R0280   R0290   766,702   R0300   50,147   R0300   50,147   R0300   50,147   R0300   S0,147   R0310   R0310   R0310   R0310   R0310   R0330			+
Non-life and health similar to non-life			816.850
Non-life excluding health			
Health similar to non-life			<del></del>
Life and health similar to life, excluding health and index-linked and unit-linked R0320   R0320   R0320   R0320   R0320   R0330   R03300	•		+
Health similar to life		-	
Deposits to cedants			
Deposits to cedants	Life excluding health and index-linked and unit-linked	R0330	
R0360   797     Reinsurance receivables   R0370   74,804     Receivables (trade, not insurance)   R0380   5,166     R0370   R0380   5,166     R0380   R0390		R0340	
Reinsurance receivables         R0370         74,804           Receivables (trade, not insurance)         R0380         5,166           Own shares (held directly)         R0390	Deposits to cedants	R0350	32,544
Receivables (trade, not insurance)         R0380         5,166           Own shares (held directly)         R0390         ————————————————————————————————————	Insurance and intermediaries receivables	R0360	797
Own shares (held directly)         R0390           Amounts due in respect of own fund items or initial fund called up but not yet paid in         R0400           Cash and cash equivalents         R0410         65,113           Any other assets, not elsewhere shown         R0420         225,814           Total assets         R0500         2,383,209           Solvency II value           Liabilities         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,250           Technical provisions - non-life (excluding health)         R0530         904,250           Technical provisions - scalculated as a whole         R0530         850,094           Risk margin         R0550         55,889           Technical provisions - health (similar to non-life)         R0550         55,889           Technical provisions calculated as a whole         R0550         55,889           Technical provisions - life (excluding index-linked and unit-linked)         R0650         -           Technical provisions - health (similar to life)         R0600         -           Technical provisions - health (similar to life)         R0600         -           Technical provisions calculated as a whole         R0620         -           Best Estimate	Reinsurance receivables	R0370	74,804
Amounts due in respect of own fund items or initial fund called up but not yet paid in Cash and cash equivalents   R0410	Receivables (trade, not insurance)	R0380	5,166
Cash and cash equivalents         R0410         65,113           Any other assets, not elsewhere shown         R0420         25,814           Total assets         R0500         2,383,209           Elsabilities         Solvency II value           Liabilities         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,250           Technical provisions calculated as a whole         R0530	Own shares (held directly)	R0390	
Any other assets, not elsewhere shown   R0420   25,814     Total assets   R0500   2,383,209     Solvency II value   C010     Cabilities   R0510   960,139     Technical provisions - non-life (excluding health)   R0520   904,250     Technical provisions calculated as a whole   R0530     Best Estimate   R0550   880,004     Risk margin   R0550   54,156     Technical provisions - health (similar to non-life)   R0550   51,007     Rest Estimate   R0570   R0590   4,792     Technical provisions - life (excluding index-linked and unit-linked)   R0600   - 1     Technical provisions - health (similar to life)   R0600   - 2     Technical provisions - left (excluding index-linked and unit-linked)   R0600   - 2     Technical provisions - left (excluding index-linked and unit-linked)   R0600   - 2     Technical provisions - left (excluding health and index-linked and unit-linked)   R0600   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0600   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit-linked)   R0650   - 2     Technical provisions - life (excluding health and index-linked and unit	Amounts due in respect of own fund items or initial fund called up but not yet paid in		
Total assets         R0500         2,383,209           Liabilities         Solvency II value           Technical provisions - non-life         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,250           Technical provisions calculated as a whole         R0530         805,004           Best Estimate         R0540         850,094           Risk margin         R0560         55,889           Technical provisions calculated as a whole         R0570         805,700           Best Estimate         R0570         90,700           Risk margin         R0580         51,097           Technical provisions - life (excluding index-linked and unit-linked)         R0600            Technical provisions - lealth (similar to life)         R0610            Technical provisions calculated as a whole         R0620            Best Estimate         R0620            Risk margin         R0640            Technical provisions calculated as a whole         R0650            Best Estimate         R0660            Technical provisions - life (excluding health and index-linked and unit-linked)         R0660	Cash and cash equivalents		
Liabilities         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,230           Technical provisions calculated as a whole         R0530         880,094           Best Estimate         R0540         880,094           Risk margin         R0550         54,156           Technical provisions - health (similar to non-life)         R0560         55,889           Technical provisions calculated as a whole         R0570         889           Best Estimate         R0580         51,097           Risk margin         R0600            Technical provisions - life (excluding index-linked and unit-linked)         R0600            Technical provisions calculated as a whole         R0620            Best Estimate         R0620            Risk margin         R0640            Technical provisions - life (excluding health and index-linked and unit-linked)         R0650            Technical provisions - life (excluding health and index-linked and unit-linked)         R0650            Technical provisions - life (excluding health and index-linked and unit-linked)         R0660            Rest Estimate         R0660            Ri	·		
Liabilities         C0010           Technical provisions - non-life         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,230           Technical provisions calculated as a whole         R0530	Total assets	R0500	
Technical provisions - non-life         R0510         960,139           Technical provisions - non-life (excluding health)         R0520         904,250           Technical provisions calculated as a whole         R0530         850,094           Best Estimate         R0540         850,094           Risk margin         R0550         54,156           Technical provisions - health (similar to non-life)         R0560         55,889           Technical provisions calculated as a whole         R0570         8650         51,097           Risk margin         R0580         51,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,097         1,092         1,097			
Technical provisions - non-life (excluding health) Technical provisions calculated as a whole Best Estimate Risk margin Technical provisions - health (similar to non-life) Technical provisions calculated as a whole Best Estimate Ros50 Technical provisions calculated as a whole Best Estimate Ros60 Technical provisions calculated as a whole Ros70 Best Estimate Ros90 Technical provisions - life (excluding index-linked and unit-linked) Technical provisions - health (similar to life) Technical provisions - health (similar to life) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Technical provisions - life (excluding health and index-linked and unit-linked) Ros90 Ros9		D0510	
Technical provisions calculated as a whole Best Estimate Risk margin Restor Res			
Best Estimate         R0540         850,094           Risk margin         R0550         54,156           Technical provisions - health (similar to non-life)         R0560         55,889           Technical provisions calculated as a whole         R0570			904,230
Risk margin         R0550         54,156           Technical provisions - health (similar to non-life)         R0560         55,889           Technical provisions calculated as a whole         R0570	·		850,004
Technical provisions - health (similar to non-life)  Rest Estimate Best Estimate Risk margin  Technical provisions - life (excluding index-linked and unit-linked)  Technical provisions - health (similar to life)  Technical provisions - health (similar to life)  Rest Estimate Rest Rest Rest Rest Rest Rest Rest Rest			
Technical provisions calculated as a whole  Best Estimate R0580 S1,097 Risk margin R0590 R0590 A,792  Technical provisions - life (excluding index-linked and unit-linked) R0600 - Technical provisions - health (similar to life) R0610 R0620 Best Estimate R0630 Risk margin R0640  Technical provisions - life (excluding health and index-linked and unit-linked) R0650 Technical provisions calculated as a whole R0660 Best Estimate R0660 R0660 R0660 R0660 R0670 Risk margin R0680 Technical provisions - index-linked and unit-linked	· · · · · · · · · · · · · · · · · · ·		
Best Estimate R0580 51,097 Risk margin R0590 4,792 Technical provisions - life (excluding index-linked and unit-linked) R0600 - Technical provisions - health (similar to life) R0610 - Technical provisions calculated as a whole R0620 R0630 Risk margin R0640 R0650 R0650 R0650 R0660 R	* '		33,667
Risk margin  Ros90 4,792  Technical provisions - life (excluding index-linked and unit-linked)  Ros90 Ros90 Ros90 Ros90 Ros91 Ros91 Ros91 Ros91 Ros91 Ros91 Ros91 Ros91 Ros92 Ros92 Ros92 Risk margin Ros930 Ros93 Ros93 Ros94 Ros94 Ros95	*		51.097
Technical provisions - life (excluding index-linked and unit-linked)  Technical provisions - health (similar to life)  Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - life (excluding health and index-linked and unit-linked)  Technical provisions calculated as a whole  Best Estimate  Ro650  Technical provisions calculated as a whole  Best Estimate  Ro660  Ro660  Best Estimate  Ro670  Risk margin  Technical provisions - index-linked and unit-linked  Ro680  Technical provisions - index-linked and unit-linked			<del></del>
Technical provisions - health (similar to life)  Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - life (excluding health and index-linked and unit-linked)  Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - life (excluding health and index-linked and unit-linked)  Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - index-linked and unit-linked  Rof600  Technical provisions - index-linked and unit-linked			
Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - life (excluding health and index-linked and unit-linked)  Technical provisions calculated as a whole  Best Estimate  Ro660  Best Estimate  Ro670  Risk margin  Technical provisions - index-linked and unit-linked  Ro680  Technical provisions - index-linked and unit-linked			
Best Estimate R0630 Risk margin R0640 Technical provisions - life (excluding health and index-linked and unit-linked) R0650 Technical provisions calculated as a whole R0660 Best Estimate R0670 Risk margin R0680 Technical provisions - index-linked and unit-linked R0690			1
Risk margin Technical provisions - life (excluding health and index-linked and unit-linked) Technical provisions calculated as a whole Best Estimate Risk margin Ro660 Ro670 Risk margin Ro680 Technical provisions - index-linked and unit-linked Ro690	<u>*</u>		
Technical provisions - life (excluding health and index-linked and unit-linked)  Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - index-linked and unit-linked  Ro680  Technical provisions - index-linked and unit-linked			
Technical provisions calculated as a whole  Best Estimate  Risk margin  Technical provisions - index-linked and unit-linked  Robert  R	· ·		
Best Estimate R0670 Risk margin R0680 Technical provisions - index-linked and unit-linked R0690			1
Technical provisions - index-linked and unit-linked R0690	•	R0670	
•	Risk margin	R0680	
Technical provisions calculated as a whole R0700	Technical provisions - index-linked and unit-linked	R0690	
	Technical provisions calculated as a whole	R0700	

Best Estimate Risk margin

Other technical provisions

Contingent liabilities

Provisions other than technical provisions

Pension benefit obligations

Deposits from reinsurers

Deferred tax liabilities

Derivatives

Debts owed to credit institutions

Financial liabilities other than debts owed to credit institutions

Insurance & intermediaries payables

Reinsurance payables

Payables (trade, not insurance)

Subordinated liabilities

Subordinated liabilities not in Basic Own Funds Subordinated liabilities in Basic Own Funds

Any other liabilities, not elsewhere shown

Total liabilities

Excess of assets over liabilities

R0710	
R0720	
R0730	>>
R0740	
R0750	
R0760	
R0770	-
R0780	-
R0790	
R0800	
R0810	
R0820	58,738
R0830	517,928
R0840	3,056
R0850	
R0860	
R0870	
R0880	339
R0900	1,540,200
R1000	843,009

Annex I S.05.01.02 Premiums, claims and expenses by line of business

			Line of Business for: non-life insurance and reinsurance obligations (direct business and accepted proportional reinsurance)									Line of Business for:						
			L	ine of business is	or: non-me	insurance and re	msurance obligations (	direct business	ани ассери	eu proportioi	iai reilisura	ance)		accepted non-proportional reinsurance				
		Medical expense insurance	Income protection insurance	Workers' compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneous financial loss	Health	Casualty	Marine, aviation, transport	Property	Total
		C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0200
Premiums written																		
Gross - Direct Business	R0110													$\geq \leq$	><	><	<b>└</b>	
Gross - Proportional reinsurance accepted	R0120	44905		2555	37085	40197	1607	189971	15020	184430				$\geq \leq$	$>\!<$	$>\!<$	$\geq$	515771
Gross - Non-proportional reinsurance accepted	R0130	$\sim$	$\geq \leq$	$>\!<$	$>\!<$	$>\!<$	$\sim$	> <	> <	$>\!<$	$\sim$	$>\!<$	$\sim$	35443	127315	131	83760	246649
Reinsurers' share	R0140	38312		2259	32348	35836	1452	146222	13133	166851				30956	114785	134	100019	682307
Net	R0200	6593		296	4737	4362	155	43749	1887	17579				4488	12530	-3	-16259	80114
Premiums earned																		
Gross - Direct Business	R0210													$>\!\!<$	$>\!\!<$	$\searrow \sim$	$\supset\!$	1
Gross - Proportional reinsurance accepted	R0220	45146		2396	29860	39187	1403	160595	9051	110398				$\geq <$	${}$	$\geq <$	$\geq \leq$	398035
Gross - Non-proportional reinsurance accepted	R0230	X	$>\!<$	$\mathbb{N}$	$>\!\!<$	$>\!<$	$\langle$	$\mathbb{N}$	$>\!\!<$	$\geq \!$	$\sim$	$\bigvee$	$\bigvee$	33534	128716	177	77713	240141
Reinsurers' share	R0240	37396		2070	25511	34158	1239	113629	7749	96540				28566	114443	174	97315	558792
Net	R0300	7749		326	4348	5029	163	46966	1301	13858				4969	14273	4	-19602	79384
Claims incurred																		
Gross - Direct Business	R0310													$>\!\!<$	$>\!\!<$	$\supset \!$	$\supset\!$	]
Gross - Proportional reinsurance accepted	R0320	27021		1598	19743	25911	1933	153170	4927	26551				$>\!\!<$	${}$	$>\!\!<$	$>\!\!<$	260853
Gross - Non-proportional reinsurance accepted	R0330	X	$>\!\!<$	$\mathbb{N}$	$>\!\!<$	$>\!\!<$	$\bigvee$	$\sim$	$>\!\!<$	$\searrow$	$>\!\!<$	$\sim$	$\sim$	16079	103518	151	32240	151987
Reinsurers' share	R0340	22946		1413	17250	23143	1738	139580	4324	23898				13791	92794	138	28733	369748
Net	R0400	4075		184	2493	2767	195	13590	603	2652				2288	10724	13	3507	43091
Changes in other technical provisions																		
Gross - Direct Business	R0410													$>\!\!<$	$\supset \!$	$>\!\!<$	$\supset \!\!\! <$	]
Gross - Proportional reinsurance accepted	R0420	0		0	0	0	0	0	0	0				$\times$	$\leq$	$\times$	$\supset\!$	0
Gross - Non- proportional reinsurance accepted	R0430	X	$>\!\!<$	$\bigvee$	$\times$	$>\!\!<$	$\mathbb{N}$	$\bigvee$	$\sim$	$\searrow$	$\times$	$\searrow$	$\bigvee$	0	0	0	0	0
Reinsurers'share	R0440	0		0	0	0	0	0	0	0				0	0	0	0	0
Net	R0500	0		0	0	0	0	0	0	0				0	0	0	0	0
Expenses incurred	R0550	7124		82	2172	1257	142	-28723	1113	19269				-2688	-9945	-7	25023	14820
Other expenses	R1200	$\times$	$>\!<$	$>\!\!<$	> <	> <	> <	$>\!<$	$>\!\!<$	$>\!\!<$	$>\!<$	$>\!<$	$>\!\!<$	$>\!\!<$	$\supset <$	$>\!\!<$	$\supset\!$	0
Total expenses	R1300	$\times$	$>\!<$	$\bigvee$	$>\!\!<$	$>\!<$	$\sim$	$\sim$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$\supset <$	$>\!\!<$	$\supset\!$	14820

			L	ine of Business fe	or: life insu	rance obligations		Life reins obliga		Total
		Health insurance	Insurance with profit participation	Index-linked and unit-linked insurance	Other life insurance	Annuities stemming from non-life insurance contracts and relating to health insurance obligations	Annuities stemming from non-life insurance contracts and relating to insurance obligations other than health insurance obligations	Health reinsurance	Life reinsurance	
		C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0300
Premiums written										
Gross	R1410									
Reinsurers' share	R1420									
Net	R1500									
Premiums earned										
Gross	R1510									
Reinsurers' share	R1520									
Net	R1600									
Claims incurred										
Gross	R1610									
Reinsurers' share	R1620									
Net	R1700									
Changes in other technical provisions										
Gross	R1710									
Reinsurers' share	R1720									
Net	R1800									
Expenses incurred	R1900									
Other expenses	R2500	$>\!\!<$	$>\!\!<$	$>\!\!<$	> <	$>\!\!<$	$\sim$	$>\!\!<$	$\nearrow$	
Total expenses	R2600	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$\sim$	$\langle$	$>\!\!<$	$\nearrow$	0

		Home Country	Top 5 cour	Top 5 countries (by amount of gross premiums written) - non-life obligations  Total Top 5 and				Total Top 5 and home country
		C0010			T			C0070
	R0010	$\sim$	FR	GG	IN	ZA	GB	
		C0080						C0140
Premiums written								•
Gross - Direct Business	R0110							
Gross - Proportional reinsurance accepted	R0120	2715	104069	58575	47318	59350	4404	276431
Gross - Non-proportional reinsurance accepted	R0130	2675	28955	449	5962	10322	81113	129477
Reinsurers' share	R0140	4700	107954	54028	48806	42828	89607	347922
Net	R0200	691	25070	4996	4474	26845	-4090	57986
Premiums earned								
Gross - Direct Business	R0210							
Gross - Proportional reinsurance accepted	R0220	1235	96804	6711	33426	43657	8971	190804
Gross - Non-proportional reinsurance accepted	R0230	2958	30110	468	8606	7110	80166	129418
Reinsurers' share	R0240	3539	99043	6447	37867	21761	93789	262446
Net	R0300	655	27871	733	4165	29006	-4653	57776
Claims incurred								
Gross - Direct Business	R0310							
Gross - Proportional reinsurance accepted	R0320	1002	61073	1846	23635	58998	10203	156757
Gross - Non-proportional reinsurance accepted	R0330	825	34590	389	1890	5758	27975	71426
Reinsurers' share	R0340	1680	83443	2088	22477	57561	34779	202030
Net	R0400	147	12219	146	3047	7195	3399	26153
Changes in other technical provisions								
Gross - Direct Business	R0410							
Gross - Proportional reinsurance accepted	R0420	0	0	0	0	0	0	0
Gross - Non- proportional reinsurance accepted	R0430	0	0	0	0	0	0	0
Reinsurers' share	R0440	0	0	0	0	0	0	0
Net	R0500	0	0	0	0	0	0	0
Expenses incurred	R0550	-307	-1921	623	-3203	-20899	9544	-16162
Other expenses	R1200	$\bigvee$	$\sim$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	0
Total expenses	R1300	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	-16162

		Home Country	Top 5 countri	es (by amount	of gross premi	ums written) -	life obligations	Total Top 5 and home country
								C0210
	R1400		FR	GG	IN	ZA	GB	Gana
n : :::	1							C0280
Premiums written								
Gross	R1410							
Reinsurers' share	R1420							
Net	R1500							
Premiums earned			-	-	-			
Gross	R1510							
Reinsurers' share	R1520							
Net	R1600							
Claims incurred			•	•				
Gross	R1610							
Reinsurers' share	R1620							
Net	R1700							
Changes in other technical provisions								
Gross	R1710							
Reinsurers' share	R1720							
Net	R1800							
Expenses incurred	R1900							
Other expenses	R2500	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$	$\searrow$	
Total expenses	R2600	$>\!\!<$	$>\!\!<$	$>\!\!<$	$\sim$	$\supset \!$	$\sim$	

						Direct b	ousiness and accep	ed proportional r	einsurance					Accep	ted non-propo	ortional reins	urance	
		Medical expense insurance	Income protection insurance	compensation insurance	Motor vehicle liability insurance	Other motor insurance	Marine, aviation and transport insurance	Fire and other damage to property insurance	General liability insurance	Credit and suretyship insurance	Legal expenses insurance	Assistance	Miscellaneo us financial loss	proportiona I health reinsurance	l casualty reinsurance	Non- proportiona I marine, aviation and transport	Non- proportiona I property reinsurance	Total Non-Life obligation
		C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110	C0120	C0130	C0140	C0150	C0160	C0170	C0180
Technical provisions calculated as a whole	R0010																	
Total Recoverables from reinsurance/SPV and Finite Re after the adjustment for expected	R0050																	
losses due to counterparty default associated to TP calculated as a whole	10030																	
Technical provisions calculated as a sum of BE and RM		$\geq \leq$	$\geq \leq$	$\geq \leq$	$\geq \leq$	~	> <	~	~	$\geq \leq$	$\geq \leq$	~	$\geq \leq$	$\geq \leq$	~	$\geq \leq$	~	$\sim$
Best estimate		$\geq \leq$	><	$\geq \leq$	$\geq \leq$	$\geq \leq$	$>\!<$	$\geq \leq$	$\geq \leq$	$\geq \leq$	>	$\geq \leq$	$\geq \leq$	$\geq \leq$	$>\!\!<$	$\gg$	$\geq \leq$	$\sim$
Premium provisions		$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	><	> <	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$
Gross	R0060	-12004		-1435	-2730	-2005	-951	-11783	-7468	-60736				-18859	-35639	-351	-25977	-179937
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected	R0140																	
losses due to counterparty default		-9841		-1423	-2099	371	-942	-5753	-15916	-66397				-11558	-18278	-363	-15637	-147836
Net Best Estimate of Premium Provisions	R0150	-2163	0	-12	-631	-2376	-9	-6030	8448	5661	0	0	0	-7301	-17361	12	-10340	-32102
Claims provisions		$>\!<$	$>\!<$	$>\!<$	$>\!<$	$>\!<$	$>\!<$	$>\!<$	$\geq \leq$	$>\!<$	$>\!<$	$>\!\!<$	$>\!<$	$>\!<$	$>\!\!<$	$\sim$	$>\!<$	$\sim$
Gross	R0160	25540		3671	19538	31371	4285	148662	40164	125415				54184	545838	238	82220	1081128
Total recoverable from reinsurance/SPV and Finite Re after the adjustment for expected	R0240																	
losses due to counterparty default		22262		3250	17222	28174	3826	134957	35465	111565				47458	485665	220	74622	964686
Net Best Estimate of Claims Provisions	R0250	3278	0	421	2316	3197	459	13705	4699	13850	0	0	0	6726	60173	18	7598	116440
Total Best estimate - gross	R0260	13536		2236	16809	29367	3335	136879	32697	64679				35325	510199	-113	56244	901191
Total Best estimate - net	R0270	1115	0	409	1685	821	450	7675	13147	19511	0	0	0	-575	42812	30	-2742	84338
Risk margin	R0280	1552		73	1301	640	86	7924	2137	11488				3167	23410	4	7166	58948
Amount of the transitional on Technical Provisions		$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	><	> <	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\langle$
Technical Provisions calculated as a whole	R0290																	
Best estimate	R0300																	
Risk margin	R0310																	
Technical provisions - total		$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	> <	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\sim$	$\langle$	$\sim$	$\langle$
Technical provisions - total	R0320	15088		2309	18110	30007	3421	144803	34834	76167				38492	533609	-109	63410	960139
Recoverable from reinsurance contract/SPV and Finite Re after the adjustment for expected	R0330			1		1												
losses due to counterparty default - total		12421	0	1827	15123	28545	2884	129204	19549	45168	0	0	0	35900	467387	-143	58985	816850
Technical provisions minus recoverables from reinsurance/SPV and Finite Re - total	R0340	2667	0	482	2986	1461	536	15599	15284	30999	0	0	0	2592	66222	34	4424	143286

#### Annex I S.19.01.21

Prior N-9

N-8

N-7

Prior N-9 N-8 N-7 N-6 N-5 N-4 N-3

N-2

N-1

N

#### Non-life Insurance Claims Information

#### **Total Non-Life Business**

Accident year / Underwriting year **Z0020** 2

Gross Claims Paid (non-cumulative)

(absolute amount)

	Devel	opm	ent v	vear
--	-------	-----	-------	------

9039

Year	0	1	2	3	4	5	6	7	8	9	10 & +
	C0010	C0020	C0030	C0040	C0050	C0060	C0070	C0080	C0090	C0100	C0110
R0100	$\times$	$\bigvee$	$\bigvee$	$\searrow$	$\bigvee$	$\searrow$	$\langle$	$\bigvee$	$\mathbb{N}$	$\sim$	1850
R0160	47923	70412	51601	28895	5387	6885	7468	3450	2419	2458	
R0170	8144	39379	21405	11614	10256	6824	3252	5135	5427		
R0180	4204	41148	21221	6974	5910	8644	7596	3733			
R0190	8820	47902	50107	18234	9293	7194	11122				

7849

8399

N-6 N-5 R0200 5347 28152 31562 13130 5511 N-4 R0210 43783 27573 10888 N-3 R0220 6245 44123 20630 27220 39740 43799 N-2 R0230 5186

N-1 R0240 9179 99158 N R0250 16206

#### **Gross undiscounted Best Estimate Claims Provisions**

(absolute amount)

#### Development year

Year	0	1	2	3	4	5	6	7	8	9	10 & +
	C0200	C0210	C0220	C0230	C0240	C0250	C0260	C0270	C0280	C0290	C0300
R0100	$>\!\!<$	$\bigvee$	$\bigvee$	$\mathbb{X}$	$\bigvee$	$\searrow$	$\bigvee$	$\searrow$	$\bigvee$	$>\!\!<$	61236
R0160				62047	55027	47221	41194	37891	32595	29085	
R0170			101916	96936	88444	79438	72121	64144	52119		
R0180		111244	97751	92553	96565	85090	74424	66384			
R0190	82938	155398	126899	117248	107373	102950	79071		_		
R0200	90435	147631	126051	107687	93009	87171		-			
R0210	98004	161028	129926	126424	116969		-				
R0220	117590	206018	170089	137853		_					

**R0240** 180716 **R0250** 187165

108980

193135

289333

157336

R0230

In Current year

# Sum of years (cumulative)

C0180 8465

226897

111437

1101620

-	
	C0170
R0100	1850
R0160	2458
R0170	5427
R0180	3733
R0190	11122
R0200	9039
R0210	8399
R0220	27220
R0230	43799
R0240	99158
R0250	16206
R0260	228411

9943
15267
9507
9615
9821
8872
10833
1620

Year end (discounted data)

	C0360
R0100	54021
R0160	24548
R0170	41053
R0180	54152
R0190	64319
R0200	71348
R0210	96755
R0220	114752
R0230	134583
R0240	258438
R0250	167158
R0260	1081128

Total

Total

			Tier 1 -	Tier 1 -		
		Total	unrestricted	restricted	Tier 2	Tier 3
		C0010	C0020	C0030	C0040	C0050
Basic own funds before deduction for participations in other financial sector as foreseen in article 68 of Delegated Regulation 2015/35		$\sim$	$>\!<$	> <	$\sim$	> <
Ordinary share capital (gross of own shares)	R0010	50000	50000	$\sim$	$\overline{}$	
Share premium account related to ordinary share capital	R0030	24341	24341	>		>
Initial funds, members' contributions or the equivalent basic own - fund item for mutual and mutual-type		21311	2.0.1	< >		$\overline{}$
undertakings	R0040					
Subordinated mutual member accounts	R0050		$>\!\!<$			
Surplus funds	R0070			$\bigvee$	$\sim$	>
Preference shares	R0090		$>\!\!<$			
Share premium account related to preference shares	R0110		$>\!\!<$			
Reconciliation reserve	R0130	571772	571772	$\sim$	><	$>\!<$
Subordinated liabilities	R0140	2022	⋘			
An amount equal to the value of net deferred tax assets	R0160	2932		$\sim$	$\sim$	29
Other own fund items approved by the supervisory authority as basic own funds not specified above	R0180	193964	193964			
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not			$\sim$	$\sim$	$\sim$	$\sim$
meet the criteria to be classified as Solvency II own funds		-	$\Longleftrightarrow$	< ->	< ->	$\leftarrow$
Own funds from the financial statements that should not be represented by the reconciliation reserve and do not meet the criteria to be classified as Solvency II own funds	R0220		$\sim$	$\sim$	$\sim$	$\sim$
Deductions		$\overline{}$	>	$\longrightarrow$	$\overline{}$	
Deductions  Deductions for participations in financial and credit institutions	R0230	$\overline{}$	$\sim$	$\sim$		_
Total basic own funds after deductions	R0290	843009	840077	0	0	29
Ancillary own funds	10270	- 0.500 <i>y</i>	<b>S</b>	$\overline{}$	$\overline{}$	$\overline{}$
Unpaid and uncalled ordinary share capital callable on demand	R0300		>	>	_	$\leq$
Unpaid and uncalled initial funds, members' contributions or the equivalent basic own fund item for mutual and			$\overline{}$	$\overline{}$		
mutual - type undertakings, callable on demand	R0310		~			
Unpaid and uncalled preference shares callable on demand	R0320		$>\!\!<$	$\bigvee$		
A legally binding commitment to subscribe and pay for subordinated liabilities on demand	R0330		$>\!<$	$\bigvee$		
Letters of credit and guarantees under Article 96(2) of the Directive 2009/138/EC	R0340		$\geq \leq$	$\langle$		$\wedge$
Letters of credit and guarantees other than under Article 96(2) of the Directive 2009/138/EC	R0350		$\geq \leq$	$\geq \leq$		
Supplementary members calls under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0360		$\geq \leq$	> <		$>\!\!<$
Supplementary members calls - other than under first subparagraph of Article 96(3) of the Directive 2009/138/EC	R0370		$\sim$	$\sim$		
Other ancillary own funds	R0390	0	$\Longrightarrow$	>		
		,				
		Total	Tier 1 -	Tier 1 -	Tier 2	Tier 3
		C0010	unrestricted C0020	restricted C0030	C0040	C0050
Total ancillary own funds	R0400	C0010	C0020	C0030	0	C0050
Available and eligible own funds	K0400		>	>		
Total available own funds to meet the SCR	R0500	843009	840077	0	0	29
Total available own funds to meet the MCR	R0510	840077	840077	0	0	~~~
Total eligible own funds to meet the SCR	R0540	843009	840077	0		29
Total eligible own funds to meet the MCR	R0550	840077	840077	0	0	$\sim$
SCR	R0580	463466	$\sim$	><	$\sim$	
MCR	R0600	115866	$>\!\!<$	$>\!\!<$	$\sim$	$\sim$
Ratio of Eligible own funds to SCR	R0620	1.8189	=	$>\!\!<$	$>\!\!<$	$>\!<$
Ratio of Eligible own funds to MCR	R0640	7.2504	$>\!<$	$>\!\!<$	$>\!\!<$	$>\!\!<$
		C0060				
Reconciliation reserve		20000	<b>&gt;</b>			
	R0700	843009	$>\!\!<$			
Excess of assets over liabilities	R0710	0	=			
Own shares (held directly and indirectly)			> <			
Own shares (held directly and indirectly) Foreseeable dividends, distributions and charges	R0720					
Own shares (held directly and indirectly) Foreseeable dividends, distributions and charges Other basic own fund items	R0730	271237	$\geq <$			
Own shares (held directly and indirectly) Foreseeable dividends, distributions and charges Other basic own fund items Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds	R0730 R0740		$\ge $			
Own shares (held directly and indirectly) Foreseeable dividends, distributions and charges Other basic own fund items Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds Reconciliation reserve	R0730	271237 571772	$\approx$			
Own shares (held directly and indirectly)  Foreseeable dividends, distributions and charges Other basic own fund items Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds Reconciliation reserve Expected profits	R0730 R0740 R0760					
Own shares (held directly and indirectly) Foresceable dividends, distributions and charges Other basic own fund items Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds Reconcillation reserve Expected profits Expected profits included in future premiums (EPIFP) - Life business	R0730 R0740 R0760 R0770	571772				
Own shares (held directly and indirectly)  Foreseeable dividends, distributions and charges Other basic own fund items Adjustment for restricted own fund items in respect of matching adjustment portfolios and ring fenced funds Reconciliation reserve Expected profits	R0730 R0740 R0760					

## Annex I

#### S.25.01.21

#### Solvency Capital Requirement - for undertakings on Standard Formula

		C0110
Market risk	R0010	412780.93
Counterparty default risk	R0020	45151.35
Life underwriting risk	R0030	0
Health underwriting risk	R0040	13474.8
Non-life underwriting risk	R0050	97786.08
Diversification	R0060	-101035.28
Intangible asset risk	R0070	0
Basic Solvency Capital Requirement	R0100	468157.88
Calculation of Solvency Capital Requirement		C0100
Operational risk	R0130	27035.73
Loss-absorbing capacity of technical provisions	R0140	0
Loss-absorbing capacity of deferred taxes	R0150	-31727.93
Capital requirement for business operated in accordance with Art. 4 of Directive 2003/41/EC	R0160	0
Solvency capital requirement excluding capital add-on	R0200	463465.68
Capital add-on already set	R0210	0
Solvency capital requirement	R0220	463465.68
Other information on SCR	D0 100	
Capital requirement for duration-based equity risk sub-module	R0400	
Total amount of Notional Solvency Capital Requirements for remaining part	R0410	
Total amount of Notional Solvency Capital Requirements for ring fenced funds  Total amount of Notional Solvency Capital Requirements for matching adjustment portfolios	R0420	
	R0430	
Diversification effects due to RFF nSCR aggregation for article 304	R0440	
Approach to tax rate		
Tappingen to the tate		

Gross solvency capital

requirement

Yes/No C0109

LAC DT

R0590

USP

C0090

None None Simplifications

C0120

# Calculation of loss absorbing capacity of deferred taxes

Approach based on average tax rate

		C0130
LAC DT	R0640	-31727.9
LAC DT justified by reversion of deferred tax liabilities	R0650	
LAC DT justified by reference to probable future taxable profit	R0660	
LAC DT justified by carry back, current year	R0670	
LAC DT justified by carry back, future years	R0680	
Maximum LAC DT	R0690	

# Annex I S.28.01.01

# Minimum Capital Requirement - Only life or only non-life insurance or reinsurance activity

Linear formula component for non-life insurance and reinsurance obligations

MCRNL Result

**C0010 R0010** 22744

Medical expense insurance and proportional reinsurance
Income protection insurance and proportional reinsurance
Workers' compensation insurance and proportional reinsurance
Motor vehicle liability insurance and proportional reinsurance
Other motor insurance and proportional reinsurance
Marine, aviation and transport insurance and proportional reinsurance
Fire and other damage to property insurance and proportional reinsurance
General liability insurance and proportional reinsurance
Credit and suretyship insurance and proportional reinsurance
Legal expenses insurance and proportional reinsurance
Assistance and proportional reinsurance
Miscellaneous financial loss insurance and proportional reinsurance
Non-proportional health reinsurance
Non-proportional casualty reinsurance
Non-proportional marine, aviation and transport reinsurance
Non-proportional property reinsurance

	1.00 (01	1,00 (01
	reinsurance/SPV)	reinsurance)
	best estimate and	written premiums
	TP calculated as a	in the last 12
	whole	months
	C0020	C0030
R0020	1115	6443
R0030		
R0040	409	292
R0050	1686	4667
R0060	822	4297
R0070	451	152
R0080	7674	18830
R0090	13147	1859
R0100	19511	17233
R0110		
R0120		
R0130		
R0140	0	4411
R0150	42812	12342
R0160	31	0
R0170	0	9591

Net (of

Net (of

# Linear formula component for life insurance and reinsurance obligations

MCRL Result

**R0200** 0

Obligations with profit participation - guaranteed benefits		
Obligations with profit participation - future discretionary benefits		
Index-linked and unit-linked insurance obligations		
Other life (re)insurance and health (re)insurance obligations		
Total capital at risk for all life (re)insurance obligations		

_	Net (of	Net (of
	reinsurance/SPV)	reinsurance/SPV)
	best estimate and	total capital at risk
	TP calculated as a	
	whole	
	C0050	C0060
R0210		$>\!\!<$
R0220		>>
R0230		$\gg$
R0240		$>\!\!<$
R0250	$\searrow$	

# Overall MCR calculation

Linear MCR SCR MCR cap MCR floor Combined MCR Absolute floor of the MCR

	C0070
R0300	22744
R0310	463466
R0320	208560
R0330	115866
R0340	115866
R0350	3900
	C0070
R0400	115866

# **Minimum Capital Requirement**